Stroke research and outcomes
Clinical studies of recovery after stroke, with disability and neurological scores alongside animal studies of infarct size and brain injury.
Browse study findings by subject ↓
Filter stroke studies
Findings from selected studies
- Disability after ischemic stroke
In MIR, 304 patients were randomized. By about day 71, disability scores fell 2.45 points with Mexidol and 2.01 with placebo (p=0.00313 in the per-protocol analysis). Adverse events were reported in 35 of 152 patients in each arm.
- Cerebrolysin added to alteplase
A study in 119 patients stopped after an interim analysis found no disability benefit at day 90. Early neurological response measures had favored Cerebrolysin.
75 of 75 source records · Showing 6
How to read the study comparison
Each row is a publication. Reviews and pooled analyses may reuse trial participants. A positive finding describes a measured outcome in that study.
| Compound / source | Setting & design | Measured findings | Interpretation & limits |
|---|---|---|---|
| English abstract | Human stroke Acute ischemic stroke after alteplase Randomized trial 119 acute ischemic-stroke patients treated with alteplase. | The trial stopped after an interim analysis found no day-90 modified Rankin Scale benefit. Early neurological responder analyses favored Cerebrolysin at days 2, 5, 10 and 30. | The trial stopped after the third interim analysis. Cerebrolysin showed no benefit on the day-90 modified Rankin Scale. Early neurological responder analyses favored treatment.Study limitations
|
2019 · Blinded rat stroke comparison of four peptide preparations Full text available | Animal / laboratory Blinded comparison of four peptide preparations in rats Animal / experimental Male Wistar rats with embolic middle cerebral artery occlusion, 23 initially randomized per arm; early deaths excluded from analysis. | Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly. | Only Cerebrolysin improved functional outcomes versus saline. None of the preparations significantly reduced lesion volume.Study limitations
|
| English abstract | Human stroke CEREHETIS post hoc analysis Human comparative study CEREHETIS post hoc analysis plus observational validation cohort | The analysis modeled hemorrhagic-transformation risk over time and reported lower hazards with Cerebrolysin in selected risk groups. | The authors modeled hemorrhagic transformation over time. This secondary analysis reuses CEREHETIS participants.Study limitations
|
2013 · Cortexin after a first ischemic stroke: 12-month cognitive follow-up Full text available | Human stroke First ischemic stroke · 12-month follow-up Randomized trial 80 patients after first ischemic stroke, 40 with Cortexin plus standard care and 40 with standard care alone. | At six months, 18/40 Cortexin recipients and 33/40 controls met the MoCA impairment threshold. At baseline the counts were 27/40 and 32/40. The paper reported significant between-group comparisons from months 6 through 12. | 80 patients. MoCA impairment at month six: 18/40 versus 33/40. The 2016 dissertation describes the same cohort.Study limitations
|
2016 · One or two Cortexin courses after stroke: cognitive outcomes in a 90-patient comparison Full text available | Human stroke Acute stroke · cognitive tests after one or two courses Human comparative study 90 patients with hemispheric ischemic stroke admitted within 24 hours. Three arms of 30. | The authors reported the largest cognitive improvements after two courses. On MMSE, the two-course group showed an earlier advantage over standard care than the single-course group. | 90 patients, 30 per arm. Earlier MMSE improvement was reported with two courses. This is a companion to the 2016 functional report.Study limitations
|
2011 · Noopept for cognitive impairment after ischemic stroke Full text available | Human stroke Post-acute cognitive recovery · two-month comparison Human comparative study 60 participants who had experienced ischemic stroke within the prior 12 months. 30 received Noopept and 30 did not. All completed the study. | In an open 60-person comparison, the authors reported greater MMSE improvement and better categorical fluency with Noopept after two months. Clock-drawing scores did not differ significantly. | 60 patients, 30 per group. Better MMSE improvement reported with Noopept. No significant difference in clock drawing.Study limitations
|
Summary of clinical findings
For education. Experimental compounds must never delay emergency stroke assessment or proven care.
Improved arm movement, a cognitive-test change, a smaller infarct in a rat and reduced mortality are different claims. This map keeps them separate. The human evidence below predominantly concerns ischemic stroke; it must not be transferred to hemorrhagic stroke or used to rank these compounds as interchangeable treatments.
Cerebrolysin ↗
The most developed stroke trial collection here, with conflicting results across settings.
CARS reports an upper-limb recovery benefit; CASTA’s primary endpoint was neutral. The Cochrane acute-stroke review found no demonstrated mortality benefit and a nonfatal serious-adverse-event signal.
Cortexin ↗
Positive functional reports, with important limits on certainty.
A one-year follow-up of 80 patients reported MoCA impairment in 18/40 with Cortexin and 33/40 with standard care at six months. At baseline the counts were 27/40 and 32/40. The institutional dissertation abstract covers the same 80 patients. It reports differences on some attention and recall measures, with no clear difference on Rankin or Barthel scores.
Semax ↗
Human neurological-recovery signals alongside extensive mechanistic work.
In the 1997 comparison, 30 treated patients and 80 controls were followed. The moderate-stroke subgroup improved by 13.0 vs 8.45 points on the Scandinavian Stroke Scale at day 6. The papers likely report the same cohort.
Mexidol ↗
Two placebo-controlled trials reported better disability scores at follow-up.
EPICA randomized 150 people. MIR randomized 304 and reported a day-71 modified Rankin Scale change of −2.45 vs −2.01 points. The journal reported adverse events in 23% of each MIR arm. The trials enrolled 454 people overall. Separately, the 318-person MEMO chronic ischemia trial found a 2.05-point MoCA advantage at treatment end.
Noopept ↗
Two-month open comparison in 60 people after ischemic stroke.
Thirty received 10 mg orally twice daily and 30 continued background care without Noopept. MMSE improvement favored Noopept in the authors’ report. Clock drawing and modified Rankin scores showed no significant difference.
Vinpotropil ↗
The stroke rehabilitation abstract gives no numerical recovery outcomes.
A separate 20-person chronic ischemia study reported a 1.9-point mean MMSE gain in 13 stage II patients. It had no control arm. A 349-person chronic ischemia report also describes improvement during treatment.
Actovegin ↗
A cognition-specific trial signal, not established overall stroke recovery.
ARTEMIDA reported better cognitive scores at six months. A systematic review found uncertain patient-important benefit; recurrent-stroke safety requires attention.
Piracetam / Nootropil ↗
An aphasia signal does not demonstrate independence or survival benefit.
A rehabilitation trial reported language improvement without demonstrated daily-activity benefit. Acute-stroke review evidence remains insufficient.
Phenotropil ↗
Limited early-recovery observations.
The outpatient report describes changes during treatment, with no adequate untreated comparison and worse tolerability at higher exposure. This cannot establish stroke efficacy.
Why the reviews can disagree
Acute treatment, early rehabilitation and later recovery recruit different patients and measure different outcomes. A positive motor-scale result does not contradict a finding of no demonstrated survival benefit. Pooling trials does not create new independent patients.
The 2023 Cochrane review included seven trials of Cerebrolysin or Cortexin. Its mortality estimate was RR 0.96 (95% CI 0.65–1.41). The estimate for nonfatal serious adverse events, RR 2.39 (1.10–5.23), comes from Cerebrolysin trials. Review and scope ↓
Two newer Cerebrolysin reviews are retained under “Needs reconciliation”: one has inconsistent significance reporting and possible overlapping CARS publications; the other has incompatible sample denominators. Their favorable claims are not treated as confirmed updates. 2025 review ↓ · 2026 review ↓
Experimental peptide studies
GK-2, GTS-115, GSB-106, GSB-214, GTS-302 and CPG have model-specific positive findings. GTS-301 was inactive in the 2026 rat experiment, while PGP and PGPL did not reproduce Semax’s transcriptional response. A related structure does not confer the same effect.
These records cannot establish human benefit, dosing, safety or a treatment window. The available Noopept-related paper leaves the results for each compound and hypoxia model unclear. Human hemorrhagic-stroke benefit is not established by the rat histology records shown here.
The source library
The 75 sources include trials, follow-up reports, reviews and related experiments. Some cover the same patients. Each entry identifies whether the findings come from the full paper or an abstract.
Human stroke
A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke
· Original journal report
Lang W, Stadler CH, Poljakovic Z, Fleet D, Lyse Study Group · Int J Stroke 8:95-104
The trial stopped after an interim analysis found no day-90 modified Rankin Scale benefit. Early neurological responder analyses favored Cerebrolysin at days 2, 5, 10 and 30.
Results and tables
Reported findings and study design
The trial stopped after an interim analysis found no day-90 modified Rankin Scale benefit. Early neurological responder analyses favored Cerebrolysin at days 2, 5, 10 and 30.
Population or model 119 acute ischemic-stroke patients treated with alteplase.
Dose, route and schedule
Cerebrolysin 30 mL/day intravenously for 10 days versus placebo, starting one hour after alteplase; acute enrollment within three hours of symptom onset. Historical study methods, not personal-use instructions.
Protocol source ↗ · Indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Day-90 modified Rankin Scale | No benefit; trial stopped at third interim analysis | |
| Early NIHSS responder analysis | Favored Cerebrolysin at days 2, 5, 10 and 30 | Secondary endpoint; response ≥6-point improvement or total score 0–1 |
| Adverse events | No between-group difference reported |
The primary disability endpoint was neutral; early secondary responder findings do not establish a day-90 benefit.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 119 acute ischemic-stroke patients treated with alteplase.
- Source reviewed
- Primary indexed abstract and publication metadata checked through Europe PMC on 1 November 2026. Full-text methods not reviewed.
Study limitations
- The primary disability endpoint was neutral; early secondary responder findings do not establish a day-90 benefit.
Reviewed 2026-11-01.
[Cerebrolysin and the optimal timing of anticoagulation resumption in stroke: combined post hoc survival analysis of the CEREHETIS trial].
Kalinin MN, Khasanova DR · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2025
The analysis modeled hemorrhagic-transformation risk over time and reported lower hazards with Cerebrolysin in selected risk groups.
Results and tables
Reported findings and study design
Post-hoc CEREHETIS analysis: Cerebrolysin plus thrombolysis/standard care 91 versus thrombolysis/standard care 147; separate validation cohort 248. Hemorrhagic transformation assessed within 14 days.
Population or model CEREHETIS post hoc analysis plus observational validation cohort
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Symptomatic hemorrhagic transformation | HR 0.245; 95% CI 0.072–0.837 | p=0.02 |
| Any hemorrhagic transformation | HR 0.543; 95% CI 0.297–0.991 | p=0.032 |
| Modeled daily hazard threshold | 0.6% per day | A modeling choice, not an observed treatment benefit |
| High-risk HTI 1–4: threshold timing | Day 2 with Cerebrolysin; days 3–5 in comparison cohorts | |
| Very-high-risk HTI 5–8: hazardous period | Through day 10 | Validation cohort only |
| Low-risk HTI=0 | Below threshold from day 1; no measurable drug effect |
Post-hoc model; this table does not recommend anticoagulation timing. These 238 trial patients overlap the related CEREHETIS publication.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- CEREHETIS post hoc analysis plus observational validation cohort
- Source reviewed
- Indexed record and available abstract checked; full text not reviewed.
Study limitations
- Model-derived anticoagulation timing is not validated prescribing guidance.
- Reuses CEREHETIS participants; separate publication does not mean independent confirmation.
- Full methods and risk of bias have not been independently assessed.
Reviewed 2026-10-07.
Cortexin after a first ischemic stroke: 12-month cognitive follow-up
M. A. Evzelman, N. A. Aleksandrova · Korsakov Journal of Neurology and Psychiatry. 2013;113(10):36–39.
At six months, 18/40 Cortexin recipients and 33/40 controls met the MoCA impairment threshold. At baseline the counts were 27/40 and 32/40. The paper reported significant between-group comparisons from months 6 through 12.
Results and tables
Reported findings and study design
The Oryol study assessed cognition after a first ischemic stroke. Baseline testing occurred during days 1–7. The dissertation gives the same two groups and describes simple randomization.
Population or model 80 patients after first ischemic stroke, 40 with Cortexin plus standard care and 40 with standard care alone.
Dose, route and schedule
10 mg intramuscularly each morning for 10 days, repeated at 3, 6 and 9 months. Both groups received standard care. Testing at baseline and months 3, 6, 9 and 12 included MoCA, MMSE and a ten-word recall test.
Protocol source ↗ · Original journal methods, Results and Figure 1 narrative. The university-hosted dissertation abstract matches the population and regimen.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MoCA impairment at 6 months | 18/40 (45%) vs 33/40 (83%) | Cortexin plus standard care vs standard care. · Reported p<0.05 |
| MoCA impairment at baseline | 27/40 (68%) vs 32/40 (80%) | The baseline proportions differed before treatment. |
| Delayed word recall | Improved in the Cortexin group | Reported p<0.05 for improvement |
| Immediate word recall | No significant between-group difference | |
| Schulte attention test | The dissertation abstract reports a between-group difference at later visits. | p=0.023 and p=0.016 |
| Modified Rankin and Barthel scores | No clear between-group difference in the dissertation abstract |
The institutional author abstract covers the same 80 participants. See the stroke research page for the archive link.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 80 patients after first ischemic stroke, 40 with Cortexin plus standard care and 40 with standard care alone.
- Source reviewed
- Original journal methods, Results and Figure 1 narrative. The university-hosted dissertation abstract matches the population and regimen.
Study limitations
- Baseline MoCA impairment rates differed. The paper describes random assignment but does not establish allocation concealment or masking.
- The active-arm 12-month narrative is ambiguous. The month-six comparison uses explicit denominators. Aleksandrova’s dissertation abstract describes the same cohort.
Reviewed 2026-11-14.
One or two Cortexin courses after stroke: cognitive outcomes in a 90-patient comparison
L. A. Belova, and colleagues · Korsakov Journal of Neurology and Psychiatry. 2016;116(8 Suppl 2):40–43.
The authors reported the largest cognitive improvements after two courses. On MMSE, the two-course group showed an earlier advantage over standard care than the single-course group.
Results and tables
Reported findings and study design
Three parallel arms. Assessments included MMSE, MoCA, five-word recall, clock drawing and frontal-function testing.
Population or model 90 patients with hemispheric ischemic stroke admitted within 24 hours. Three arms of 30.
Dose, route and schedule
10 mg Cortexin intramuscularly twice daily for 10 days, given as one course or with a second 10-day course after a 10-day interval. All three arms received standard care. The third arm received standard care alone.
Protocol source ↗ · Original publisher text and comparison with the same year’s 90-person clinical and functional report.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MMSE comparison versus standard care | Advantage from visit 3 with two courses and visit 4 with one course | Reported pairwise timing. All groups improved over time. |
| Baseline cognitive differences | No statistically significant group differences reported | p>0.05 |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 90 patients with hemispheric ischemic stroke admitted within 24 hours. Three arms of 30.
- Source reviewed
- Original publisher text and comparison with the same year’s 90-person clinical and functional report.
Study limitations
- The authors describe envelope randomization. Masking and concealment are unclear. The paper reports several cognitive outcomes.
- The same authors’ 90-person functional report uses matching arms and doses. The two publications are grouped together.
Reviewed 2026-11-14.
Noopept for cognitive impairment after ischemic stroke
A. V. Amelin, A. Yu. Ilyukhina, A. A. Shmonin · Korsakov Journal of Neurology and Psychiatry. 2011;111(10):44–46. PMID 22500312.
In an open 60-person comparison, the authors reported greater MMSE improvement and better categorical fluency with Noopept after two months. Clock-drawing scores did not differ significantly.
Results and tables
Reported findings and study design
Open prospective comparison. The average time since stroke was 6.14 months in the active group and 6.83 months in controls. Outcomes included MMSE, drawing, verbal associations and clinician-rated change.
Population or model 60 participants who had experienced ischemic stroke within the prior 12 months. 30 received Noopept and 30 did not. All completed the study.
Dose, route and schedule
10 mg Noopept orally twice daily after meals for two months. Both groups continued indicated antihypertensive, antiplatelet and lipid-lowering therapy.
Protocol source ↗ · Original Russian article text and indexed English abstract. Numerical image tables were not independently transcribed.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MMSE at 2 months | Both groups improved. Improvement was greater with Noopept. | Reported statistically significant between-group comparison |
| Categorical verbal associations | Improved in the Noopept arm | The article reports a significant change. |
| Clock drawing and modified Rankin Scale | No significant between-group differences reported | |
| Completion and reported tolerability | 60/60 completed | The authors reported no significant adverse reactions. |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 60 participants who had experienced ischemic stroke within the prior 12 months. 30 received Noopept and 30 did not. All completed the study.
- Source reviewed
- Original Russian article text and indexed English abstract. Numerical image tables were not independently transcribed.
Study limitations
- The open design and concomitant care limit causal interpretation. Exact tabulated effects require legible original tables.
- The 12 months in the abstract refer to the window for previous stroke. The treatment course lasted two months.
Reviewed 2026-11-14.
Mexidol after moderate ischemic stroke: MIR placebo-controlled trial
Ethylmethylhydroxypyridine succinate, followed by Mexidol Forte 250 tablets.
N. A. Shamalov, A. I. Fedin, G. S. Rakhimbaeva, et al. · Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(8 Suppl 2):40–53. NCT06437626.
By about day 71, disability scores changed by −2.45 points with Mexidol and −2.01 with placebo (p=0.00313). At follow-up, 60% vs 41% scored 0–1 on the modified Rankin Scale. The paper reported adverse events in 35 of 152 participants in each arm.
Results and tables
Reported findings and study design
International double-blind randomized parallel-group comparison in first-ever moderate ischemic stroke. 152 participants per group. Primary per-protocol analysis included 141 Mexidol and 138 placebo recipients.
Population or model 304 randomized, 152 per arm. Primary per-protocol analysis: 141 Mexidol and 138 placebo.
Dose, route and schedule
Standard care plus 500 mg Mexidol intravenously twice daily for 10 days, followed by 250 mg orally three times daily for 60 days. Controls received standard care and matching IV and oral placebo.
Protocol source ↗ · Published full-text trial tables and ClinicalTrials.gov results (NCT06437626).
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Change in disability score (mRS) | −2.45 vs −2.01 points | Mexidol vs placebo, 141 vs 138 analyzed · Day 71 · p=0.00313 |
| mRS score 0–1 | 60% vs 41% | Mexidol vs placebo, per protocol · Day 71 · p=0.002 |
| Participants with an adverse event | 35/152 (23%) in each arm | Journal counts: 42 events vs 43 · p=1.000 |
MIR disability outcomes by analysis population
| Outcome | Per protocol: Mexidol vs placebo | Intention to treat: Mexidol vs placebo |
|---|---|---|
| mRS change at end of oral phase | −2.45 vs −2.01 (p=0.00313) | −2.32 vs −1.90 (p=0.00384) |
| mRS 0–1 at end of oral phase | 60% vs 41% (p=0.002) | 57% vs 39% (p=0.002) |
| mRS ≥3 at end of oral phase | 16% vs 28% (p=0.016) | 20% vs 32% (p=0.019) |
| Median mRS change after IV phase | −1 vs −1 (p=0.8) | −1 vs −1 (p=0.8) |
Table 3. Lower mRS scores indicate less disability. The registry reports arm-level 95% confidence intervals for primary change of −2.70 to −2.23 and −2.25 to −1.87. The article’s prose and table differ in how they label the primary estimate.
The primary endpoint favored Mexidol over placebo at the end of the 70-day treatment course. The registry lists serious adverse events in six vs four participants and deaths in two vs one. The trial gives limited information on rare harms and on people receiving reperfusion.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 304 randomized, 152 per arm. Primary per-protocol analysis: 141 Mexidol and 138 placebo.
- Source reviewed
- Published full-text trial tables and ClinicalTrials.gov results (NCT06437626).
Study limitations
- The trial enrolled patients with first-ever moderate ischemic stroke who did not receive reperfusion. Generalizability to thrombolysis or thrombectomy is uncertain.
- The primary analysis was per protocol. The intention-to-treat result also favored Mexidol. The US registry first posted the study after completion.
- The journal reports 35 participants with events in each arm. The registry lists 36 vs 39 participants in its nonserious-events category. The reports do not reconcile those totals.
Reviewed 2026-11-14.
Mexidol after hemispheric ischemic stroke: EPICA placebo-controlled trial
Ethylmethylhydroxypyridine succinate IV and 125 mg oral tablets.
L. V. Stakhovskaya, N. A. Shamalov, D. R. Khasanova, et al. · Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(3 Suppl 2):55–65. NCT02793687.
At days 67–71 the mean modified Rankin Score was 1.10 with Mexidol and 1.46 with placebo (p=0.04). Scores of 0–2 were reported in 59/61 vs 53/63. Serious adverse events occurred in 1/75 vs 3/75.
Results and tables
Reported findings and study design
Double-blind, randomized multicenter parallel groups. 75 assigned per arm, with 61 and 63 in the per-protocol analysis.
Population or model 150 randomized, 75 per arm. Per-protocol results: 61 Mexidol and 63 placebo.
Dose, route and schedule
500 mg Mexidol by intravenous infusion daily for 10 days, followed by 125 mg orally three times daily for eight weeks. The comparator followed the same schedule with matching placebo.
Protocol source ↗ · Published full-text trial tables and ClinicalTrials.gov results (NCT02793687).
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mean disability score (mRS) | 1.10 vs 1.46 points | Mexidol vs placebo, 61 vs 63 analyzed · Days 67–71 · p=0.04 |
| mRS score 0–2 | 59/61 (96.7%) vs 53/63 (84.1%) | Days 67–71 · p=0.039 |
| Mean NIHSS score | 1.7 vs 2.2 points | Days 67–71 · p=0.035 |
| Serious adverse events | 1/75 vs 3/75 | No deaths reported in either arm |
The journal reported no significant between-arm differences on the Barthel Index, Frontal Assessment Battery or cognitive screening questionnaire. The 2018 translation and later EPICA subgroup reports use this cohort.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 150 randomized, 75 per arm. Per-protocol results: 61 Mexidol and 63 placebo.
- Source reviewed
- 2018 journal English translation of the 2017 original, checked with registry results.
Study limitations
- Twenty-six randomized participants were outside the per-protocol analysis. The trial registry first posted after completion.
- The 2018 translation, age subgroup report, and later analysis combining EPICA with MIR reuse trial participants. EPICA and MIR ran in different periods.
Reviewed 2026-11-14.
Vinpotropil during early ischemic stroke rehabilitation
A. N. Kuznetsov, V. D. Daminov · Zh Nevrol Psikhiatr Im S S Korsakova. 2007;Suppl 21:52–56.
Patients reported that the fixed combination was well tolerated and more convenient to take than separate tablets. The abstract does not quantify a stroke recovery outcome.
Results and tables
Reported findings and study design
Findings described in words
Population or model Patients in early ischemic stroke rehabilitation. Enrollment and arm sizes are absent from the abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Tolerability and convenience | Favorable patient reports for the fixed combination. | No numerical neurological or functional outcome in the abstract. |
The original report is needed for enrollment, intervention schedules, and outcomes by arm.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Patients in early ischemic stroke rehabilitation. Enrollment and arm sizes are absent from the abstract.
- Source reviewed
- Indexed English abstract of the original Russian journal report.
Study limitations
- The original tables are needed for group sizes, drug regimen and neurological or functional outcomes.
- The chronic cerebral ischemia reports involve a different clinical setting.
Reviewed 2026-11-14.
Adjunctive Cerebrolysin therapy following mechanical thrombectomy for tandem right internal carotid artery and middle cerebral artery occlusion with residual post-procedural perfusion deficit: a case report
· Journal publication
Eichel R, Mausbach S, Teicher M, Bornstein NM · Journal of medicine and life 19(8)
After thrombectomy and adjunctive Cerebrolysin, NIHSS improved from 7 to 1 within hours. The patient was discharged on day five with mild residual cognitive deficits. Recovery was already unfolding around treatment initiation, so the case cannot isolate a Cerebrolysin contribution.
Results and tables
Reported findings and study design
After thrombectomy and adjunctive Cerebrolysin, NIHSS improved from 7 to 1 within hours. The patient was discharged on day five with mild residual cognitive deficits. Recovery was already unfolding around treatment initiation, so the case cannot isolate a Cerebrolysin contribution.
Population or model One 57-year-old man after thrombectomy and carotid stenting for tandem arterial occlusion.
Dose, route and schedule
Cerebrolysin 30 mL in 250 mL saline intravenously daily for four consecutive days, beginning after thrombectomy and stenting. Reported case regimen, not a prescribing recommendation.
Protocol source ↗ · Original full-text XML, methods and results checked
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical observation | One 57-year-old man | |
| NIHSS | 7 → 1 within hours | After thrombectomy and adjunctive care; no isolated drug effect |
| Hospital course | Discharged on day 5 with mild residual cognitive deficits | |
| Reported Cerebrolysin regimen | 30 mL in 250 mL saline intravenously daily for 4 days | First dose at 12:24 after the procedure |
Single case without a comparator. Successful recanalization, spontaneous recovery and concurrent care are alternative explanations. August publication newly indexed in October, not an October trial.
Source for these results ↗ · Reviewed 2026-10-31
- Population / setting
- One 57-year-old man after thrombectomy and carotid stenting for tandem arterial occlusion.
- Source reviewed
- Original full-text XML from Europe PMC checked on 31 October 2026, including methods and results. Case timeline and four-day infusion regimen checked; treatment cannot be separated from reperfusion and spontaneous recovery.
Study limitations
- Single case without a comparator. Successful recanalization, spontaneous recovery and concurrent care are alternative explanations. August publication newly indexed in October, not an October trial.
Reviewed 2026-10-31.
Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients.
Fan D, Krishnamurthi R, Harris P, Barber PA, Guan J · Annals of clinical and translational neurology (2019); PMID 31019991
In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.
Results and tables
Reported findings and study design
In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.
34 patients recruited within 3 days of stroke; 50 age-matched controls without stroke.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Biomarker association | Lower baseline cGP and cGP/IGF-1 ratio in stroke; baseline ratio correlated with day-90 NIHSS and its change | No correlation coefficient or absolute concentration in the indexed abstract |
| Participants | 34 stroke patients; 50 controls | |
| Assessment schedule | Baseline within 3 days; days 7 and 90 |
An association with endogenous cGP does not show that giving cGP or GZK-111 improves recovery.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 34 stroke patients recruited within three days; 50 age-matched controls
- Source reviewed
- Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
- Observational association is not evidence that CPG administration improves stroke recovery. Small cohort; causal interpretation and external predictive validity remain unresolved.
- Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Reviewed 2026-11-01.
Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study.
Staszewski J, Dębiec A, Strilciuc S, Gniadek-Olejniczak K, Piusinska-Macoch R, Balo D, Harston G, Stępień A, Brzozowski K, Zięcina P, Narloch J, Wierzbicki M, Piasecki P · Translational stroke research. 2025.
Functional independence at 90 days was more frequent in the treated cohort, while mortality did not differ significantly.
Results and tables
Reported findings and study design
Functional independence at 90 days was more frequent in the treated cohort, while mortality did not differ significantly.
50 treated thrombectomy patients versus 50 propensity-matched historical controls; selected for small infarct core, good collaterals and successful reperfusion.
Population or model 50 prospectively treated thrombectomy patients and 50 matched historical controls
Dose, route and schedule
30 mL intravenously within eight hours of stroke onset, continued to day 21, followed by a second course at days 69–90. This was adjunctive treatment after mechanical thrombectomy.
Protocol source ↗ · Primary publication full text
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Functional independence, mRS 0–2 | 68% versus 44% | Treated versus historical control; 50 per group · Day 90 · OR 2.7, 95% CI 1.2–6.1; p=0.016 |
| Secondary intracranial hemorrhage | 14% versus 40% | Source abstract percentages; historical comparison · Follow-up · Reported RR 0.37, 95% CI 0.14–0.95; p=0.02 |
| NIHSS | 3 [IQR 4] versus 6 [IQR 9] | Median neurological deficit score; lower is better · Day 7 · p=0.01 |
| Barthel Index | 77 [IQR 32] versus 63 [IQR 50] | Treated versus control · Day 30 · p=0.03 |
| Barthel Index | 86 [IQR 22] versus 75 [IQR 29] | Treated versus control · Day 90 · p=0.01 |
| Mortality | 2% versus 6% at day 30; 8% versus 12% at day 90 | No significant between-group difference · p>0.1 |
| Adjusted functional-outcome association | OR 7.5; 95% CI 1.8–30.9 | Model-adjusted estimate, distinct from the crude OR · Day 90 |
Nonrandomized historical comparison. The 12-month report follows the same NCT04904341 cohort. The source’s hemorrhage RR is reproduced rather than recalculated from rounded percentages.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 50 prospectively treated thrombectomy patients and 50 matched historical controls
- Source reviewed
- Original full text from the repository, with numerical results and table context checked on 1 November 2026
Study limitations
- Nonrandomized, single-center historical-control comparison; matching cannot remove unmeasured confounding.
- Selected patients had good collateral circulation and successful reperfusion.
- The 2026 twelve-month report (PMID 41739286) follows this cohort; it is not an independent trial.
Reviewed 2026-11-01.
Cerebrolysin as an adjuvant therapy after mechanical thrombectomy in large vessel occlusion cardioembolic stroke: a propensity score matching analysis.
ElBassiouny A, Shehata MSA, Zaki AS, Bedros RY, El-Sudany AH, Nasser AA · Frontiers in neurology. 2025.
Both the full cohort and propensity-matched subset favored Cerebrolysin for disability outcomes; cognition did not differ significantly.
Results and tables
Reported findings and study design
Both the full cohort and propensity-matched subset favored Cerebrolysin for disability outcomes; cognition did not differ significantly.
75 treated and 75 historical controls with cardioembolic stroke after thrombectomy; propensity-matched analysis retained 51 per group.
Population or model 75 treated and 75 historical-control patients with cardioembolic stroke after thrombectomy
Dose, route and schedule
30 mL daily for 14 days, beginning within eight hours after thrombectomy. The indexed regimen is recorded without inferring an administration route.
Protocol source ↗ · Primary publication full text
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Functional independence, mRS 0–2 | 48/75 (64%) versus 26/75 (34.7%) | Treated versus historical controls · Day 90 · p<0.001 |
| Matched functional independence | 33/51 (65%) versus 16/51 (31%) | Rounded percentages as printed in Table 2 · Day 90 · p<0.001 |
| Any hemorrhagic transformation | 15/75 (20%) versus 43/75 (57.3%) | Matched: 13/51 (25.5%) versus 29/51 (56.9%) · p<0.001 full cohort; p=0.001 matched |
| Symptomatic hemorrhagic transformation | 2/75 (2.7%) versus 31/75 (41.3%) | Matched: 2/51 (3.9%) versus 22/51 (43.1%) · p<0.001 in both comparisons |
| Overall mortality | 4/75 (5.3%) versus 24/75 (32%) | Matched: 3/51 (5.9%) versus 12/51 (24%, rounded as printed) · p<0.001 as reported |
| MoCA cognition | 30 [23–30] versus 29.5 [17–30] | Median [range]; no significant difference · Day 90 · p=0.13; matched p=0.20 |
| Matched NIHSS | 5 [1–15] versus 6 [1–16] | No significant difference in the matched subset · Day 90 · p=0.08 |
| Sepsis | 3/75 (4.0%) versus 10/75 (13.3%) | Matched: 2/51 versus 6/51; difference no longer significant · p=0.045 full cohort; p=0.14 matched |
Disability and neurological scores: full versus matched samples
| Outcome / time | Treated n=75 | Historical n=75 | p | Matched treated n=51 | Matched control n=51 | p |
|---|---|---|---|---|---|---|
| mRS day 14 | 3 [1–6] | 4 [1–6] | 0.02 | 3 [1–6] | 4 [1–6] | 0.044 |
| mRS day 30 | 2 [0–5] | 3 [1–6] | <0.001 | 3 [0–5] | 3 [1–6] | 0.004 |
| mRS day 90 | 2 [0–6] | 3 [0–6] | <0.001 | 2 [0–6] | 4 [0–6] | <0.001 |
| NIHSS day 14 | 7 [2–19] | 10 [2–28] | <0.001 | 7 [2–18] | 10 [2–28] | <0.001 |
| NIHSS day 30 | 5 [0–17] | 8 [1–20] | 0.01 | 5.5 [1–16] | 8 [1–20] | 0.02 |
| NIHSS day 90 | 5 [0–16] | 6 [1–16] | 0.02 | 5 [1–15] | 6 [1–16] | 0.08 |
| MoCA day 90 | 30 [23–30] | 29.5 [17–30] | 0.13 | 30 [23–30] | 30 [17–30] | 0.20 |
Selected Table 2 outcomes; medians [range]. Full and matched samples are analyses of the same participants, not separate trials.
Historical controls and residual confounding limit causal interpretation. Large outcome differences are observations, not confirmed treatment effects. Table 3 contains inconsistent subrows; questionable cells are not silently corrected.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 75 treated and 75 historical-control patients with cardioembolic stroke after thrombectomy
- Source reviewed
- Original full text from the repository, with numerical results and table context checked on 1 November 2026
Study limitations
- Nonrandomized historical comparison; propensity matching does not establish causation.
- Selected cardioembolic stroke population; results cannot be generalized to all stroke patients.
Reviewed 2026-11-01.
Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke: <i>post hoc</i> secondary analysis of the CEREHETIS trial.
Kalinin MN, Khasanova DR · Frontiers in pharmacology. 2025.
A secondary analysis found lower hemorrhage hazards in the higher-risk subgroup. The proposed anticoagulation windows are model outputs, not validated treatment instructions.
Results and tables
Reported findings and study design
A secondary analysis found lower hemorrhage hazards in the higher-risk subgroup. The proposed anticoagulation windows are model outputs, not validated treatment instructions.
238 middle-cerebral-artery infarctions from the existing CEREHETIS trial; low HTI 0 versus higher HTI 1–4 risk groups; 14-day survival modeling.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Symptomatic hemorrhagic transformation | HR 0.245; 95% CI 0.072–0.837 | Cerebrolysin versus control in higher-risk subgroup · 14-day analysis · p=0.020 |
| Any hemorrhagic transformation | HR 0.543; 95% CI 0.297–0.991 | Higher-risk subgroup · 14-day analysis · p=0.032 |
| Modeled risk-equilibrium window | Days 1–3 versus days 3–5 | Treated versus control in higher-risk subgroup; exploratory model, not a measured safe-start rule |
| Low-risk modeled stabilization | Day 2 in both groups | HTI 0 subgroup |
| Analyzed subset | 238 of 341 original intention-to-treat participants | Middle-cerebral-artery infarction restriction |
The authors reanalyzed CEREHETIS data. Their risk model does not establish when an individual patient should resume anticoagulation.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 238 thrombolysis-treated patients in a secondary CEREHETIS analysis
- Source reviewed
- Original full text from the repository, with numerical results and table context checked on 1 November 2026
Study limitations
- Post hoc analysis of an existing trial, not a new randomized comparison.
- Modeled risk thresholds do not establish a safe time to start anticoagulation; prospective validation is required.
Reviewed 2026-11-01.
Evaluating the Effect of Cerebrolysin as an Adjuvant to Standard Therapy in Patients with Acute Ischemic Stroke: A Prospective Observational Study.
Kandasamy G, Arumugam V, Orayj K, Alshahrani AM, Alanazi TS, Hmlan A, Venugopal JP · Medicina (Kaunas, Lithuania). 2025.
In a non-randomized 143-patient stroke comparison, NIHSS fell from 9.90 to 3.40 with adjunctive Cerebrolysin versus 10.10 to 4.80 with standard care; more treated patients reached the reported independence categories.
Results and tables
Reported findings and study design
In a non-randomized 143-patient stroke comparison, NIHSS fell from 9.90 to 3.40 with adjunctive Cerebrolysin versus 10.10 to 4.80 with standard care; more treated patients reached the reported independence categories.
Prospective single-center observational comparison: Cerebrolysin + standard care 73; standard care 70.
Population or model 143 adults: 73 adjunctive treatment, 70 standard care; recruited in 2016–2018
Dose, route and schedule
30 mL intravenously daily for 14 days, added to standard stroke care.
Protocol source ↗ · Primary publication indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| NIHSS score, mean ± SD | 9.90 ± 2.90 → 3.40 ± 1.40 versus 10.10 ± 2.80 → 4.80 ± 1.30 | Adjunctive versus standard-care arm · Baseline → day 14 · t=6.19; p<0.001 |
| Shift to minor stroke severity | 43.84% versus 25.71% | Adjunctive versus standard care · Day 14 |
| Slight dependency | 38.36% versus 20% | Barthel Index category; adjunctive versus standard care · Day 14 |
| Full independence | 16.44% versus 5.71% | Barthel Index category; adjunctive versus standard care · Day 14 |
| Studied regimen | 30 mL intravenously daily for 14 days |
Treatment was not randomized; these are short-term associations, not proof that the drug caused the between-group difference.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 143 adults: 73 adjunctive treatment, 70 standard care; recruited in 2016–2018
- Source reviewed
- Indexed primary-publication abstract checked; full methods and tables not appraised.
Study limitations
- Nonrandomized single-center comparison with only 14 days of follow-up.
- Published in 2025 but participants were recruited in 2016–2018; publication date is not the study date.
Reviewed 2026-11-01.
C-REGS2-A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke.
Vosko MR, Sanak D, Do Y, Vatanagul JS, Roushdy T, Bornstein NM, Vester JC, Brainin M · International journal of stroke : official journal of the International Stroke Society; 2025 Oct
C-REGS2 associated Cerebrolysin with better 90-day disability and cognitive outcomes in 1,769 patients. It was a prospective observational comparison, with no significant between-group difference in deaths or serious adverse events.
Results and tables
Reported findings and study design
C-REGS2 associated Cerebrolysin with better 90-day disability and cognitive outcomes in 1,769 patients. It was a prospective observational comparison, with no significant between-group difference in deaths or serious adverse events.
1,865 enrolled in 16 countries; target population 1,769 (1,021 treated, 748 controls); baseline NIHSS 8–15. Multilevel-adjusted, non-randomized comparison.
Dose, route and schedule
In this observational registry, the median Cerebrolysin dose was 30 mL and median treatment duration was ten days. These are cohort medians, not a uniform prescribed schedule; route and frequency are not given in the indexed abstract.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Ordinal mRS | MW 0.6157; 95% CI 0.5910–0.6404 | Cerebrolysin versus standard care; MW=0.5 represents no ordering advantage · Day 90 · p<0.0001 |
| Excellent recovery, mRS 0–1 | Derived OR 2.74; 95% CI 2.12–3.60 | Multilevel-adjusted dichotomized outcome · Day 90 · p<0.0001 |
| Functional independence, mRS 0–2 | Derived OR 2.88; 95% CI 2.28–3.68 | Multilevel-adjusted dichotomized outcome · Day 90 · p<0.0001 |
| Ordinal NIHSS | MW 0.5792 (95% CI 0.5576–0.6008) at day 21; 0.5781 (0.5561–0.6002) at day 90 | Adjusted treatment comparison · Days 21 and 90 · Both p<0.0001 |
| Ordinal MoCA | MW 0.5530; 95% CI 0.5282–0.5778 | Adjusted comparison · Day 90 · p<0.0001 |
| Deaths and serious adverse events | No significant group difference | ITI safety analyses, including non-fatal serious events · Study follow-up · All p≥0.1 |
| Missing outcomes | 90.9% valid primary mRS entries; 5.7% final-visit dropout | Different completeness measures; not the same denominator |
| Typical exposure | Median 30 mL; median duration 10 days |
The MW statistic and odds ratios are not percentage-point gains in independence. Adjustment cannot remove every confounder. The paper reports manufacturer funding and relevant author relationships; safety neutrality is not proof of absence of rare harm.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- C-REGS2: 1,865 enrolled; 1,769 analyzed (1,021 treated, 748 controls), 16 countries; recruitment 2018–2024
- Source reviewed
- Original full-text methods, effectiveness and safety sections checked; supplementary raw outcome tables not extracted
Study limitations
- Nonrandomized, open-label treatment; adjustment does not remove unmeasured confounding.
- This is observational effectiveness research, not a randomized trial.
- Full methods and risk of bias have not been independently assessed.
Reviewed 2026-11-01.
Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study.
Homberg V, Jianu DC, Stan A, Strilciuc Ș, Chelaru VF, Karliński M, Brainin M, Heiss WD, Muresanu DF, Enderby PM · Stroke; 2025 Apr
With speech therapy in both groups, the Cerebrolysin group showed greater improvement in language scores at 90 days than placebo, alongside neurological improvement.
Results and tables
Reported findings and study design
In ESCAS, day-90 language improvement was 35.579 ± 16.316 points with Cerebrolysin plus speech therapy versus 20.774 ± 12.486 with placebo plus speech therapy. The between-group difference was 14.805 points (95% CI 9.521–20.089).
Population or model ESCAS: 132 enrolled; 123 in intention-to-treat analysis
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Western Aphasia Battery change | 35.579 ± 16.316 versus 20.774 ± 12.486 points | p<0.001 |
| Between-group language difference | 14.805 points; 95% CI 9.521–20.089 | p<0.001 |
| Enrollment / analysis | 132 enrolled; 123 intention-to-treat; 120 per protocol |
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- ESCAS: 132 enrolled; 123 in intention-to-treat analysis
- Source reviewed
- Indexed record and available abstract checked; full text not reviewed.
Study limitations
- Pilot trial in a selected nonfluent-aphasia population; generalizability is limited.
- Difference between enrolled and analyzed populations requires full-methods review.
- Full methods and risk of bias have not been independently assessed.
Reviewed 2026-10-07.
Cerebrolysin after Endovascular Thrombectomy in Stroke: 12‑Month Functional Outcomes in a Propensity‑Matched Cohort.
Staszewski J, Dębiec A, Gniadek-Olejniczak K, Stępień A, Piusinska-Macoch R, Strilciuc S, Balo D, Harston G, Brzozowski K, Zięcina P, Narloch J, Wierzbicki M, Piasecki P · Translational stroke research; 2026 Feb
At 12 months, treated patients had better functional measures, while cumulative mortality was 18% in both groups.
Results and tables
Reported findings and study design
At 12 months, treated patients had better functional measures, while cumulative mortality was 18% in both groups.
Prespecified extension of the same 50 treated and 50 matched historical controls reported at three months, NCT04904341.
Population or model Selected thrombectomy patients; propensity-matched historical controls
Dose, route and schedule
Cerebrolysin: 30 mL/day for 21 days starting immediately after endovascular thrombectomy, with a second 21-day course at days 69–90. Route is not specified in the indexed abstract. This was adjunctive treatment in an observational comparison with historical controls.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Functional independence | Adjusted OR 6.10; 95% CI 1.64–22.66 | mRS 0–2; model-adjusted association with Cerebrolysin · 12 months · p<0.01 |
| Favorable mRS shift | Common OR 3.57; 95% CI 1.42–8.93 | Shift across disability-score categories · 12 months · p<0.01 |
| Mortality | 18% in each group | Cumulative deaths; no mortality difference · 12 months |
| Institutional care among survivors | 6% versus 19% | Treated versus controls; survivor denominator, not all randomized patients · 12 months · Unadjusted OR 0.26; 95% CI 0.07–0.99 |
| Barthel Index | 92 [82–100] versus 83 [73–93] | Median [Q1–Q3]; treated versus controls · 12 months · p=0.01 |
This is follow-up of the existing observational cohort, not another trial. Adjusted odds ratios are not absolute response rates. Historical control and selected-patient effects remain possible.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- Selected thrombectomy patients; propensity-matched historical controls
- Source reviewed
- Original indexed abstract with documented cohort linkage. Numerical results checked on 1 November 2026.
Study limitations
- Twelve-month follow-up of the same 50 treated and 50 historical-control patients in PMID 40325343, registration NCT04904341; not an independent trial.
- Historical controls and residual confounding limit causal interpretation.
- The three- and twelve-month reports follow the same cohort.
- Full methods and risk of bias have not been independently assessed.
Reviewed 2026-11-01.
[Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation].
Kalinin MN, Khasanova DR · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2024
Reported treatment associations varied with baseline hemorrhagic-transformation risk; the low-risk subgroup showed neutral effects.
Results and tables
Reported findings and study design
Post-hoc CEREHETIS analysis, 238 stroke patients; HTI-stratified hemorrhagic-transformation risk; favorable outcome mRS≤2 at day 90.
Population or model CEREHETIS post hoc analysis: 238 patients
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Symptomatic HT treatment-effect heterogeneity | I² 36.98–69.3%; H² 1.59–3.26 | |
| Any HT treatment-effect heterogeneity | I² 18.33–32.39%; H² 1.22–1.48 | |
| Reported reduction in symptomatic HT | 3.8% at HTI=0 versus 14.3% at HTI≥2 | p=0.120 versus p<0.001 |
| Reported reduction in any HT | 0.6% versus 19.5% in those risk strata | p=0.864 versus p<0.001 |
| Reported mRS-score reduction | 2.1% versus 63% in those risk strata | p=0.893 versus p<0.001 |
| Reported increase in favorable outcomes | 2% versus 19.2% in those risk strata | p=0.634 versus p<0.001 |
Risk-stratum percentages are reported as printed, without relabeling them as absolute percentage-point differences. This is a post-hoc analysis of an existing cohort.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- CEREHETIS post hoc analysis: 238 patients
- Source reviewed
- Indexed record and available abstract checked; full text not reviewed.
Study limitations
- Post hoc subgroup analysis is exploratory.
- Overlaps the CEREHETIS trial and potentially its other language/version reports.
- Full methods and risk of bias have not been independently assessed.
Reviewed 2026-10-07.
[Cerebrolysin with reperfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CEREHETIS trial].
Kalinin MN, Khasanova DR · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2025
A 33-patient CEREHETIS imaging subgroup associated adjunctive Cerebrolysin with lower day-14 blood–brain barrier permeability and infarct volume, alongside altered diffusion-imaging measures.
Results and tables
Reported findings and study design
A 33-patient CEREHETIS imaging subgroup associated adjunctive Cerebrolysin with lower day-14 blood–brain barrier permeability and infarct volume, alongside altered diffusion-imaging measures.
Cerebrolysin + thrombolysis + standard care 16; thrombolysis + standard care 17. Imaging at 24 hours and day 14.
Population or model CEREHETIS imaging subgroup: 16 treated and 17 controls
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Axial diffusivity contrast | 259.05 × 10⁻⁶ mm²/s; 95% CI 142.19–375.91 | Model-predicted marginal contrast, treated versus control · Day 14 · p<0.001 |
| Radial diffusivity contrast | 209.89 × 10⁻⁶ mm²/s; 95% CI 106.91–312.87 | Same model contrast · Day 14 · p<0.001 |
| Fractional anisotropy contrast | 185.13 × 10⁻⁴; 95% CI 22.88–347.37 | Scaled FA units as reported · Day 14 · p=0.021 |
| BBB permeability contrast | −1.41 mL/100 g/min; 95% CI −1.69 to −1.13 | Model contrast · Day 14 · p<0.001 |
| Infarct volume contrast | −6.98 mL; 95% CI −10.13 to −3.82 | Model contrast · Day 14 · p<0.001 |
| Early imaging comparison | No significant group differences | At 24 hours after thrombolysis |
Imaging measures are surrogate endpoints in a small subgroup. This shares the CEREHETIS cohort and is not an independent clinical trial.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- CEREHETIS imaging subgroup: 16 treated and 17 controls
- Source reviewed
- Indexed record and available abstract checked; full text not reviewed.
Study limitations
- Small subgroup and surrogate imaging endpoints.
- Same CEREHETIS program as other analyses; not independent replication.
- Full methods and risk of bias have not been independently assessed.
Reviewed 2026-11-01.
[Evaluation of the efficiency of combined neuroprotection and high-intensity magnetotherapy in the medical rehabilitation of patients with ischemic stroke].
Cortexin-containing rehabilitation regimens; one intervention group also received citicoline (Recognan), with high-intensity magnetotherapy. This is not a comparison of isolated Cortexin alone.
Butko DY, Davydov AT, Koneva ES, Lyadov KV, Okhotnikova AA, Reutsky IA, Shcheglova MA, Yakovlev EV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2026
The authors reported greater short-term improvement in rehabilitation measures with Cortexin-containing regimens and high-intensity magnetotherapy than with standard treatment. One intervention group also received citicoline.
Results and tables
Reported findings and study design
98 stroke patients: groups of 34, 33 and 31; 59 women, 39 men; ages 40–68, mean 54 ± 1.5. Cortexin 10 mg IM twice daily for 15 days in groups I/II; both also had magnetic stimulation. Group I additionally received citicoline 1,000 mg/day for 21 days.
Population or model 98 patients undergoing ischemic-stroke rehabilitation; groups of 34, 33 and 31
Dose, route and schedule
Combination arm: Cortexin 10 mg intramuscularly twice daily for 15 days, Recognan 1,000 mg orally once daily for 21 days, and high-intensity magnetic muscle stimulation. Outcomes cannot be attributed to Cortexin alone.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Lower-limb spasticity reduction at day 14 | 27% group I; 25% group II; 15% group III | |
| Patients with improved vertebral-artery flow velocities | 52%, 41% and 20% in groups I, II and III | |
| Group-I discharge NIHSS | 9.3 ± 0.2 points | |
| Group-I discharge Rankin score | 2.1 ± 0.2 points |
Multiple treatment components differ. The abstract calls the study observational while also describing randomization; allocation appraisal remains unresolved.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 98 patients undergoing ischemic-stroke rehabilitation; groups of 34, 33 and 31
- Source reviewed
- Indexed record and abstract checked. Full methods and risk of bias have not been independently assessed.
Study limitations
- No Cortexin-only arm; effects cannot be attributed to Cortexin independently.
- The abstract describes the study as both observational and randomized; design needs reconciliation against the full paper.
- Follow-up assessments at days 14 and 21 do not establish lasting functional benefit.
Reviewed 2026-10-06.
Cerebrolysin for acute ischaemic stroke
Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K · Cochrane Database Syst Rev 10:CD007026. PMID 37818733
The pooled mortality analysis of Cerebrolysin or Cortexin found probably little or no difference (RR 0.96, 95% CI 0.65–1.41; 6 trials, 1,689 participants).
Results and tables
Reported findings and study design
2023 Cochrane review: seven randomized trials, 1,773 participants; includes a 272-person Cortexin trial. Mortality analysis: six trials, 1,689 participants.
Population or model Cochrane review: 7 RCTs, including one Cortexin trial with 272 participants
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| All-cause mortality | RR 0.96; 95% CI 0.65–1.41 | Cerebrolysin/Cortexin pooled; moderate-certainty evidence |
| Non-death attrition | RR 0.72; 95% CI 0.38–1.39 | Six trials, 1,689; very low certainty |
| Any serious adverse event | RR 1.16; 95% CI 0.81–1.66 | Cerebrolysin: three trials, 1,335 |
| Fatal serious adverse event | RR 0.90; 95% CI 0.59–1.38 | Cerebrolysin: three trials, 1,335 |
| Nonfatal serious adverse event | RR 2.39; 95% CI 1.10–5.23 | Cerebrolysin: three trials, 1,335 |
| Nonfatal SAE: 30 mL/day for ten days subgroup | RR 2.87; 95% CI 1.24–6.69 | Two trials, 1,189; cumulative dose 300 mL |
| Any adverse event | RR 1.03; 95% CI 0.92–1.14 | Four trials, 1,607 |
Mortality mixes two preparations; the serious-event estimates concern Cerebrolysin. A risk ratio whose interval crosses 1 is not a proven reduction or increase. Underlying trials overlap other pages.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Cochrane review: 7 RCTs, including one Cortexin trial with 272 participants
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- The pooled estimate is not Cortexin-only.
- The potential increase in nonfatal serious adverse events concerned Cerebrolysin and should not automatically be assigned to Cortexin.
Reviewed 2026-09-29.
Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial
Cerebrolysin preparation administered intravenously as an adjunct to acute stroke care, compared with placebo; background treatment included aspirin.
Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators · Stroke · PMID 22282884
The combined primary outcome showed no significant benefit. A favorable signal in more severe strokes arose in post-hoc analysis.
Results and tables
Reported findings and study design
CASTA: 1,070 patients, randomized within 12 hours; Cerebrolysin 529 versus placebo 541. Intravenous 30 mL/day for ten days plus aspirin 100 mg/day; 90-day follow-up.
Population or model CASTA: 1,070 acute ischemic-stroke patients; randomized within 12 hours; 90-day follow-up
Dose, route and schedule
Cerebrolysin: 30 mL intravenously daily for 10 days, starting within 12 hours of stroke onset. Background treatment included aspirin 100 mg/day; the comparison used placebo.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Combined primary outcome | No significant between-group difference | |
| Severe-stroke subgroup: NIHSS outcome | OR 1.27; lower CI bound 0.97 | Exploratory subgroup with baseline NIHSS>12 |
| Severe-stroke subgroup: mRS outcome | OR 1.27; lower CI bound 0.90 | Exploratory subgroup |
| Severe-stroke subgroup: 90-day mortality | 10.5% Cerebrolysin versus 20.2% placebo | Abstract reports HR 1.9661 and lower CI bound 1.0013; direction follows the source |
Primary result was neutral. Subgroup findings are post hoc; the incomplete confidence intervals are reproduced without inventing upper bounds.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- CASTA: 1,070 acute ischemic-stroke patients; randomized within 12 hours; 90-day follow-up
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- The severe-stroke subgroup is exploratory, not confirmation of efficacy.
- The meta-analyses that include CASTA already account for this trial.
Reviewed 2026-10-05.
Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.
Porcine brain-derived peptide mixture; equivalence to other hydrolysates is not assumed · Journal publication
Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A · Stroke
The exploratory trial reports better upper-limb motor recovery at day 90.
Results and tables
Reported findings and study design
CARS: randomized double-blind placebo comparison in early stroke rehabilitation. Cerebrolysin 30 mL/day for 21 days, starting 24–72 hours after stroke; rehabilitation for 21 days.
Population or model Stroke patients receiving standardized rehabilitation; CARS trial
Dose, route and schedule
Cerebrolysin: 30 mL once daily for 21 days, beginning 24–72 hours after stroke onset, alongside a standardized rehabilitation program. The indexed abstract does not specify the route.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Action Research Arm Test at day 90 | Mann–Whitney estimator 0.71; 95% CI 0.63–0.79 | p<0.0001 |
| Global status across 12 outcome scales | Mann–Whitney estimator 0.62; 95% CI 0.58–0.65 | p<0.0001 |
| Premature discontinuation | 3.8% |
These are nonparametric effect-size estimators, not 71% or 62% improvements. Authors describe the trial as exploratory; the indexed abstract does not state the sample size.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Stroke patients receiving standardized rehabilitation; CARS trial
- Source reviewed
- Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.
Study limitations
- Authors call for a larger confirmatory trial. Rehabilitation and timing define the setting; this is not evidence of healthy-person enhancement.
Reviewed 2026-09-30.
Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke.
Porcine brain-derived peptide mixture; equivalence to other hydrolysates is not assumed · Journal publication
Chang WH, Park CH, Kim DY, Shin YI, Ko MH, Lee A, Jang SY, Kim YH · BMC neurology
Among 70 randomized stroke patients, overall motor improvement did not differ significantly between Cerebrolysin and placebo. A severe-impairment subgroup favored Cerebrolysin; imaging changes were also reported.
Results and tables
Reported findings and study design
Among 70 stroke patients, overall motor recovery did not differ significantly between Cerebrolysin and placebo. A severe-impairment subgroup favored Cerebrolysin. Imaging findings were also reported.
Population or model 70 subacute stroke patients randomized 35 per group
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Overall motor recovery | No significant between-group difference | |
| Severe motor-impairment subgroup | Greater improvement with Cerebrolysin | p<0.05 |
| Randomized participants | 35 Cerebrolysin; 35 placebo |
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 70 subacute stroke patients randomized 35 per group
- Source reviewed
- Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.
Study limitations
- Subgroup findings should not replace the overall result or be generalized to all stroke patients.
Reviewed 2026-09-30.
Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials.
Porcine brain-derived peptide mixture; equivalence to other hydrolysates is not assumed · Journal publication
Guekht A, Vester J, Heiss WD, Gusev E, Hoemberg V, Rahlfs VW, Bajenaru O, Popescu BO, Doppler E, Winter S, Moessler H, Muresanu D · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Individual-participant analysis reports a favorable motor-recovery result during early rehabilitation.
Results and tables
Reported findings and study design
Individual-patient meta-analysis of CARS-1/2; 442 patients. Cerebrolysin 30 mL/day for three weeks starting 24–72 hours after stroke; standardized 21-day rehabilitation.
Population or model 442 participants in the pooled CARS-1 and CARS-2 analysis
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ARAT at day 90 | Mann–Whitney effect size 0.62 | p<0.0001 |
| Early NIHSS at days 14/21 | Mann–Whitney effect size 0.59 | p<0.002 |
| NNT for clinically relevant early NIHSS change | 7.1; 95% CI 4–22 |
Combines two trials already represented elsewhere. Mann–Whitney estimates are not percentage improvements; last-observation-carried-forward analysis was used.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 442 participants in the pooled CARS-1 and CARS-2 analysis
- Source reviewed
- Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.
Study limitations
- Reanalysis of existing trials, not a new independent cohort. The CARS totals already include these participants.
Reviewed 2026-09-30.
ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.
Deproteinized calf-blood derivative · Journal publication
Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD · Stroke
The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.
Results and tables
Reported findings and study design
ARTEMIDA: 503 patients age ≥60, MoCA≤25, randomized within one week of stroke: Actovegin 248 versus placebo 255. Up to twenty IV infusions 2,000 mg/day, then oral 1,200 mg/day for six months; follow-up 12 months.
Population or model 503 patients aged 60 or older after ischemic stroke; ARTEMIDA
Dose, route and schedule
Actovegin: 2,000 mg/day for up to 20 intravenous infusions, followed by 1,200 mg/day orally, for six months of treatment in total. Treatment began within one week of ischemic stroke.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ADAS-cog+ change at month 6 | −6.8 Actovegin versus −4.6 placebo | |
| Estimated treatment difference | −2.3 points; 95% CI −3.9 to −0.7 | p=0.005 |
| Recurrent ischemic stroke | More frequent with Actovegin, not statistically significant | Event counts absent from abstract |
Adjusted treatment difference is retained as −2.3 rather than replacing it with subtraction of the rounded means.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 503 patients aged 60 or older after ischemic stroke; ARTEMIDA
- Source reviewed
- Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Study limitations
- Clinical importance and replication remain unresolved. The safety imbalance cannot establish causation or be dismissed as proof of safety. Disease-specific results do not establish healthy-person enhancement.
Reviewed 2026-09-30.
Actovegin in the management of patients after ischemic stroke: A systematic review.
Deproteinized calf-blood derivative · Journal publication
la Fleur P, Baizhaxynova A, Reynen E, Kaunelis D, Galiyeva D · PloS one
The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.
- Population / setting
- Five controlled studies after ischemic stroke; one randomized trial and four observational studies
- Source reviewed
- Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Study limitations
- Heterogeneous evidence precluded meta-analysis. This review includes ARTEMIDA and is not an independent additional trial.
Reviewed 2026-09-30.
Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke
Aliferova VM, Dadasheva MN, Doronin BM, Kovalenko AV, Lokshtanova TM, Martynov MIu, Meshkova KS, Salimov KA, Stakhovskaia LV, Chefranova ZhIu, Shamalov NA · Zh Nevrol Psikhiatr Im S S Korsakova 114(4):41-46. PMID 24874316
Double-blind placebo-controlled comparison of repeated Cortexin, one course followed by placebo, and placebo. Authors reported functional and pharmacoeconomic benefits.
Results and tables
Reported findings and study design
272 acute-stroke patients in a multicenter double-blind placebo comparison. Three treatment sequences; Cortexin 10 mg IM three times daily, with one or two ten-day courses; 70-day observation and four visits.
Population or model ESCORT; 272 acute ischemic-stroke patients
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Best reported treatment sequence | Two Cortexin courses | Exact scale scores and arm-level results absent from abstract |
This is the 272-participant Cortexin trial included in later reviews, not another independent trial population.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- ESCORT; 272 acute ischemic-stroke patients
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- Read alongside the independent 2023 Cochrane assessment; favorable scales do not establish mortality benefit.
- The related ESCORT publications describe one trial.
Reviewed 2026-09-29.
New possibilities of neuroprotection in the treatment of ischemic stroke
Skoromets AA, Stakhovskaia LV, Belkin AA, Shekhovtsova KV, Kerbikov OB, Burenchev DV, Gavrilova OV, Skvortsova VI · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 19431244
The double-blind multicenter report described improvement in neurological and functional scales compared with placebo.
Results and tables
Reported findings and study design
62 acute-stroke patients in a double-blind placebo comparison: Cortexin 32 versus placebo 30. Cortexin 20 mg/day IM for ten days, beginning within six hours; assessments through day 28.
Population or model 62 acute hemispheric ischemic-stroke patients; 32 Cortexin and 30 placebo; treatment started within six hours
Dose, route and schedule
Cortexin: 20 mg intramuscularly daily for 10 days, beginning within the first six hours of stroke onset, alongside stroke care.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Neurological and functional scales | Authors report favorable outcomes | NIHSS, mRS and Barthel measured; numerical scores and effect sizes absent from the abstract |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 62 acute hemispheric ischemic-stroke patients; 32 Cortexin and 30 placebo; treatment started within six hours
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Small trial; random sequence generation is not established by the abstract.
- No numerical treatment effect or adequate assessment of uncommon harms is available in the abstract.
Reviewed 2026-10-05.
Efficacy of cortexin in acute and recovery periodes of hemispheric ischemic stroke
Belova LA, Mashin VV, Abramova VV, Proshin AN, Ovsjannikova AN · Zh Nevrol Psikhiatr Im S S Korsakova 116(10):38-42. PMID 27845314
Compares one course, repeated courses and basic therapy, using neurological, mobility and cognitive scales. Authors reported greater improvement with repeated treatment.
Results and tables
Reported findings and study design
Three groups of 30 compared one course, two courses and standard care. The investigators assessed disability, activities of daily living, mobility and cognition.
Population or model 90 patients with hemispheric ischemic stroke, 30 per arm.
Dose, route and schedule
Cortexin: 20 mg/day intramuscularly, divided as 10 mg plus 10 mg, in one or two ten-day courses; the two-course schedule included a ten-day interval.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Functional independence (modified Rankin Scale) | Two courses favored at visits 4 and 5 versus standard care | Reported p<0.05 |
| Activities of daily living (Barthel Index) | Two-course advantage reported from visit 3 | Reported p<0.05 |
The cognitive companion describes matching arms, sample and regimen.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 90 patients with hemispheric ischemic stroke, 30 per arm.
- Source reviewed
- Original publisher text, methods and results. The 2016 cognitive companion has matching arms and dosing.
Study limitations
- Blinding and allocation safeguards are not established by the abstract.
- Natural recovery and co-treatment complicate interpretation.
Reviewed 2026-11-14.
Efficacy of Korteksin in acute period of hemispheric ischemic stroke
Belova LA, Mashin VV, Abramova VV, Slastyon EY, Belov DV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 30132453
The authors reported the greatest neurological improvement in one repeated-course group.
Results and tables
Reported findings and study design
122 acute-stroke patients in four groups: 30 single-course 20 mg/day, 30 repeated-course 20 mg/day, 30 basic care, and 32 repeated-course 30 mg/day. Courses lasted ten days, with a ten-day break.
Population or model 122 ischemic-stroke patients in four groups (30, 30, 30 and 32)
Dose, route and schedule
The comparison included Cortexin 20 mg/day intramuscularly (10 mg plus 10 mg) in one course or two ten-day courses separated by ten days, basic treatment alone, and a 30 mg/day arm (10 mg three times daily) using two ten-day courses separated by ten days. All Cortexin arms were adjunctive to basic stroke treatment.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Best reported neurological regression | Repeated 30 mg/day group | NIHSS, mRS, Barthel, Rivermead, MMSE and MoCA used; numerical group scores absent from the abstract |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 122 ischemic-stroke patients in four groups (30, 30, 30 and 32)
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Randomization and blinding are not established from the abstract.
- Possible participant overlap with the same group’s 2016 report remains unresolved.
- Different treatment schedules do not establish an optimal clinical regimen.
Reviewed 2026-10-05.
Use of cortexin in the early rehabilitation period of ischemic stroke of moderate severity
Nurguzhaev ES, Mitrokhin DA, Izbasarova ASh, Nurguzhaev AE, Raimkulov BN, Abdil'manova BR · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 19672239
Motor and cognitive outcomes favored adjunctive Cortexin over basic therapy during short follow-up.
Results and tables
Reported findings and study design
68 stroke rehabilitation patients: Cortexin 35 versus basic treatment 33; age 60.5 ± 2.8 years. Add-on Cortexin 10 mg IM daily for ten days.
Population or model 68 early-rehabilitation patients; 35 adjunctive Cortexin, 33 basic therapy
Dose, route and schedule
Cortexin: 10 mg intramuscularly daily for 10 days, added to basic treatment during early ischemic-stroke rehabilitation. Controls received basic treatment alone.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Global-state improvement | 27/35 (77.1%) versus 18/33 (54.5%) | End of treatment |
| Motor/cognitive rehabilitation comparison | Cortexin favored | p<0.05 |
| Treatment adverse effects | None observed in this small comparison |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 68 early-rehabilitation patients; 35 adjunctive Cortexin, 33 basic therapy
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Allocation and masking are unclear in the abstract.
- Short follow-up and limited safety reporting do not establish sustained independence or safety.
Reviewed 2026-10-05.
Post-stroke cognitive impairment in young patients
Shchepankevich LA, Rerikh KV, Gribacheva IA, Popova TF, Taneeva EV, Tyazhelnikov NE, Sokolova DV, Boznyakov AV · Zh Nevrol Psikhiatr Im S S Korsakova 124(8):92-96. PMID 39269301
Open prospective report of cognition and quality-of-life changes during follow-up.
Results and tables
Reported findings and study design
Open observational report of 30 stroke survivors aged 18–45; repeated Cortexin courses.
Population or model 30 post-stroke adults aged 18–45
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MoCA baseline | 25.1 ± 1.4 points | |
| MoCA after second course, visit 4 | 28.4 ± 1.3 points | |
| Delayed MoCA, visit 5 | 28.0 ± 1.1 points | |
| Quality-of-life improvement | Recorded at visit 4 and maintained at visit 5 | No numerical SF-36 score printed |
Before/after results without a concurrent control. The abstract does not give a numerical p-value for these MoCA changes.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 30 post-stroke adults aged 18–45
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- No randomized untreated comparator described.
- Recovery over time cannot be separated reliably from a treatment effect.
Reviewed 2026-09-29.
Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes
Fedin AI, Khairova EN, Artyukov OP, Timchenko LV, Bazhenova OA, Gaiduk NV, Zykov MV · Zh Nevrol Psikhiatr Im S S Korsakova 125(12):60-67. PMID 41524350
Compares routes of active Cortexin administration. Both groups received active drug; the placebo injections maintained masking.
Results and tables
Reported findings and study design
490 stroke patients aged 30–80: IV-form Cortexin 246 versus IM-form Cortexin 244. Mean age 63.97 ± 8.5 years; 54.1% men, 45.9% women. Two ten-day courses with ten days between; follow-up 90 days. Both groups received active Cortexin.
Population or model 490 stroke patients: 246 IV-first, 244 IM; double-dummy active comparison
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| mRS 0–2 at day 90 | 93.64% IV-form versus 86.50% IM-form | |
| NIHSS reduction | 3.93 versus 3.72 points | |
| MMSE increase | 4.11 versus 3.88 points | p=0.249 |
| Adverse events | 74 events in 60 IV-group patients versus 51 in 41 IM-group patients | p>0.05 |
The first course used 10 mg twice daily by the assigned active route with matching placebo by the other route; both then received IM Cortexin. This tests route/form equivalence, not efficacy versus no Cortexin.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 490 stroke patients: 246 IV-first, 244 IM; double-dummy active comparison
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- This is an active-route equivalence comparison, not evidence of benefit versus no Cortexin.
- Noninferiority margin and full analysis require review; publication year is 2025 despite later indexing.
Reviewed 2026-09-29.
Cortexin in the complex treatment of post stroke epilepsy
Gafurov BG, Gafurov ShB · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 20873481
The report describes improved clinical effects and EEG findings alongside anti-seizure treatment.
Results and tables
Reported findings and study design
46 patients with post-stroke epilepsy: Cortexin add-on 29 versus basic care 17. Background Depakine-chrono averaged 750 mg/day; Cortexin 10 mg IM for 15 days.
Population or model 46 patients with post-stroke epilepsy; 29 adjunctive Cortexin, 17 basic treatment
Dose, route and schedule
Cortexin: 10 mg intramuscularly during a 15-day course, added to vascular drugs and Depakine Chrono (mean 750 mg/day). Cortexin administration frequency is not specified in the indexed abstract. Outcomes concern combination treatment.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical and EEG effects | Add-on group favored | Seizure counts and numerical EEG effect sizes not given |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 46 patients with post-stroke epilepsy; 29 adjunctive Cortexin, 17 basic treatment
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Concurrent treatment prevents attribution to Cortexin alone.
- The abstract does not establish sustained seizure freedom, prevention of epilepsy or randomized allocation.
Reviewed 2026-10-05.
Comparative analysis of efficacy of certain neuroprotectors in ischemic stroke
Skorokhodov AP, Dudina AA, Kolesnikova EA, Koron AE, Kobantsev IuA, Sedova AA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 18193579
Authors described broadly similar clinical effects in moderate ischemic stroke and some practical advantages for Cortexin.
Results and tables
Reported findings and study design
Two comparative series: Cortexin versus Nootropil in 35 patients; Cortexin versus Cerebrolysin in 45 patients.
Population or model Two comparative series: 35 patients in a Cortexin–Nootropil comparison and 45 in a Cortexin–Cerebrolysin comparison
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Moderate-stroke clinical effects | Described as similar across the compared preparations | Arm sizes, effect estimates and noninferiority margins absent |
The two series and three preparations should not be treated as a single randomized ranking.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Two comparative series: 35 patients in a Cortexin–Nootropil comparison and 45 in a Cortexin–Cerebrolysin comparison
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Allocation, masking and usable between-group effect estimates are unclear.
- This is not a reliable head-to-head ranking or proof of equivalence.
Reviewed 2026-10-05.
Semax in acute hemispheric ischemic stroke: 1997 clinical and EEG comparison
· Journal article
Format: Journal article · Reviewed: Indexed abstract
E. I. Gusev, V. I. Skvortsova, E. Iu. Zhuravleva, A. V. Vanichkin · Neurology Bulletin. 1997;29(3–4):32–38. Related 1997 Korsakov publication: PMID 11517472.
In moderate stroke, the day-6 Scandinavian Stroke Scale gain was 13.0 vs 8.45 points with Semax versus control. Day-21 gains were 21.4 vs 17.2, with no significant difference marked for that time point.
Results and tables
Reported findings and study design
30 Semax-treated patients and 80 conventional-care controls. Clinical and electrophysiological observations included the Scandinavian, Orgogozo and original clinical scales.
Population or model 110 people, 30 Semax plus usual care and 80 usual-care controls. Moderate stroke: 16 vs 55. Severe stroke: 14 vs 25 (Table 1).
Dose, route and schedule
The Neurology Bulletin full text reports 12, 18 or 24 mg/day intranasally in two administrations for the first five days. The companion abstract reports 12 and 18 mg/day and mentions five- and ten-day courses. The numerical results table comes from the five-day full-text report.
Protocol source ↗ · Neurology Bulletin full text and indexed Korsakov companion abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Scandinavian Stroke Scale gain, moderate stroke | +13.0 vs +8.45 points | 16 Semax vs 55 controls · Day 6 · p<0.05 |
| Scandinavian Stroke Scale gain, severe stroke | +11.3 vs +1.0 points | 14 Semax vs 25 controls · Day 6 · p<0.001 |
Changes from baseline by clinical scale (Table 1)
| Severity / scale | Day 6 Semax vs control | Day 21 Semax vs control |
|---|---|---|
| Moderate / Scandinavian | +13.0 vs +8.45 | +21.4 vs +17.2 |
| Moderate / Orgogozo | +20.0 vs +15.9 | +39.0 vs +29.02 |
| Moderate / original scale | +4.0 vs +2.45 | +5.6 vs +5.09 |
| Severe / Scandinavian | +11.3 vs +1.0 | +18.3 vs +13.1 |
| Severe / Orgogozo | +15.0 vs +5.5 | +27.5 vs +24.1 |
| Severe / original scale | +4.0 vs −0.22 | +6.67 vs +7.0 |
Point changes as reported. No significant between-arm effects are marked at day 21 in Table 1. Table 2 has a conflicting severe-control denominator.
The day-6 signal comes from a historical comparison with unresolved allocation and masking. The probable 1997 Korsakov companion publication is indexed as PMID 11517472.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 110 people, 30 Semax plus usual care and 80 usual-care controls. Moderate stroke: 16 vs 55. Severe stroke: 14 vs 25 (Table 1).
- Source reviewed
- Neurology Bulletin full text, Tables 1–2, and the indexed Korsakov companion abstract.
Study limitations
- Allocation and masking are unclear. Systematic adverse-event data are unavailable in the checked sections.
- Matching authors and 30/80 enrollment indicate probable overlap with the 1997 Korsakov paper. The source record treats the two as companion reports.
- The digitized Table 2 lists a severe-control number inconsistent with Table 1. The extracted results use Table 1. The Cerebrolysin and Cronassial comparisons are historical.
Reviewed 2026-11-14.
The efficacy of Semax in the treatment of patients at different stages of ischemic stroke
Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted · Journal publication
E I Gusev, M Yu Martynov, E V Kostenko, L V Petrova, S N Bobyreva · Zh Nevrol Psikhiatr Im S S Korsakova. 118(3 Vyp 2):61–68
The report links treatment and rehabilitation timing to plasma BDNF and functional outcomes.
Results and tables
Reported findings and study design
110 stroke patients: 43 men and 67 women, mean age 58.0 ± 9.7 years. Early rehabilitation 89 ± 9 days versus late 214 ± 22 days; each subdivided by Semax use.
Population or model 110 stroke patients; early/late rehabilitation groups with and without Semax
Dose, route and schedule
Semax: 6,000 micrograms/day in two ten-day courses separated by a 20-day interval during post-stroke rehabilitation. The route and within-day schedule are not specified in the indexed abstract.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Semax regimen | 6,000 micrograms/day | Two ten-day courses separated by a 20-day interval |
| BDNF and Barthel outcomes | Higher BDNF and improved recovery reported | No numerical between-group effect size in the abstract |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 110 stroke patients; early/late rehabilitation groups with and without Semax
- Source reviewed
- Indexed citation and English abstract checked; full methods and risk of bias not appraised.
Study limitations
- Randomization and blinding are not established by the abstract.
- BDNF association does not prove mediation; rehabilitation timing is a separate influence.
- Disease-specific findings do not establish healthy-person enhancement.
Reviewed 2026-09-30.
Piracetam for acute ischaemic stroke
Format: Systematic review · Reviewed: Abstract and reference list
S. Ricci, M. G. Celani, T. A. Cantisani, E. Righetti · Cochrane Database Syst Rev. 2012(9):CD000419
The review found insufficient evidence on dependence. A nonsignificant early-mortality trend was sensitive to baseline stroke-severity imbalance.
Results and tables
Reported findings and study design
Three acute-stroke trials, 1,002 patients aged 40–85; one trial supplied 93% of the data. Search cutoff May 2011.
Population or model Three trials, 1,002 patients; one trial supplied 93% of the data
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| One-month death trend | Approximately 31% increase; interval from 5% reduction to 81% increase | Not statistically significant |
| After severity-imbalance adjustment | Unfavorable trend no longer apparent in the large trial | |
| Dependence/function | Insufficient evidence; limited data showed no difference |
The later page date does not indicate a newly searched trial set. Adverse effects were unreported, not proven absent.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Three trials, 1,002 patients; one trial supplied 93% of the data
- Source reviewed
- Indexed abstract and included-trial list checked. The current Cochrane page dates the same DOI to 2022 but still reports a May 2011 search cutoff; this is not evidence of a newly searched trial set.
Study limitations
- Condition-specific historical review, not a conclusion about healthy-person cognition.
- Harms were not adequately reported; absence of reporting is not evidence of safety.
- The review includes participants from the trials it summarizes.
Reviewed 2026-10-02.
Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study
Format: Journal article · Reviewed: Abstract
Enderby P, Broeckx J, Hospers W, Schildermans F, Deberdt W · Clinical neuropharmacology
A 12-week placebo comparison reported an aphasia signal but no demonstrated improvement in activities of daily living. Persistence at 24 weeks was unresolved.
Results and tables
Reported findings and study design
The 158-patient rehabilitation trial found a favorable aphasia analysis at 12 weeks (p=0.02), but no demonstrated daily-living benefit. Only 88 patients were available at 24 weeks, leaving persistence uncertain.
Population or model 158 post-stroke rehabilitation patients; 137 assessed after treatment and 88 at 24 weeks
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Aachen Aphasia Test multivariate comparison | Favored piracetam at 12 weeks | p=0.02 |
| Activities of daily living | No demonstrated treatment effect | |
| Follow-up availability | 158 enrolled; 137 after treatment; 88 at week 24 |
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 158 post-stroke rehabilitation patients; 137 assessed after treatment and 88 at 24 weeks
- Source reviewed
- Europe PMC indexed abstract checked; complete trial methods not reviewed.
Study limitations
- Substantial loss to later follow-up limits interpretation.
- Aphasia findings require confirmation and do not establish healthy-person cognitive enhancement.
Reviewed 2026-10-02.
Experience using Phenotropil in outpatients during early recovery after ischemic stroke
L. V. Bagir, T. T. Batysheva, A. N. Boyko, E. V. Kostenko, T. M. Manevich, O. V. Matvievskaya · Consilium Medicum. No. 8, 2006; eight-page reprint
The report describes before/after changes in cognitive and functional measures. It also reports worse subjective tolerability in the higher-exposure group.
- Population / setting
- 120 post-stroke outpatients; two active-treatment groups
- Source reviewed
- Original article reprint, title page and indexed methods/results checked; numerical outcomes not independently reanalyzed.
Study limitations
- No untreated/placebo group in the described comparison.
- Recovery over time and other care limit causal attribution.
- Patient outcomes do not establish healthy-person performance enhancement.
Reviewed 2026-09-29.
Animal / laboratory
Blinded rat stroke comparison of four peptide preparations
· Journal of the Neurological Sciences 398:22–26
Format: Journal of the Neurological Sciences 398:22–26 · Reviewed: Reported methods, results and evidence limitations
L. Zhang et al. · Journal of the Neurological Sciences 398:22–26
Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly.
Results and tables
Reported findings and study design
Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly.
Prospective, randomized and blinded comparisons of saline, Cognistar, Cerebrolysat, Cortexin and Cerebrolysin. Serial neurological testing through day 28.
Population or model Male Wistar rats with embolic middle cerebral artery occlusion, 23 initially randomized per arm; early deaths excluded from analysis.
Dose, route and schedule
Daily intraperitoneal doses for ten days starting four hours after occlusion: Cognistar, Cerebrolysat and Cerebrolysin 2.5 mL/kg each, Cortexin 1.7 mg/kg or saline 1 mL per rat. One methods line repeats Cerebrolysin where the abstract and other sections identify Cerebrolysat.
Protocol source ↗ · Journal of the Neurological Sciences 398:22–26
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Serial functional testing | Cerebrolysin improved outcomes; Cortexin, Cerebrolysat and Cognistar did not show a comparable significant benefit | Figure 1. Neurological severity, adhesive removal and foot-fault testing. |
| Lesion volume | No significant improvement versus saline in any treatment group | Functional and histological outcomes are separate. |
Animal ischemia results do not transfer between differently manufactured formulations.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Male Wistar rats with embolic middle cerebral artery occlusion, 23 initially randomized per arm; early deaths excluded from analysis.
- Source reviewed
- Journal of the Neurological Sciences 398:22–26
Study limitations
- Animal ischemia results do not transfer between differently manufactured formulations.
Reviewed 2026-11-09.
Rationally designed peptides relieve ischemic stroke by targeting TRPM2 intramolecular interactions.
Yao J, You Q, Liu X, Zhen W, Fang M, Luo Y, Wu J, Mai Z, Yu P, Yang F, Yang W · Pharmacological research (2026); PMID 41932669
M2IP inhibited TRPM2 at submicromolar concentrations in experimental assays and reduced brain injury in a mouse stroke model. It targets an inter-subunit interface involved in channel activation.
- Population / setting
- TRPM2 electrophysiology and calcium imaging; mouse ischemic-stroke model
- Source reviewed
- Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
- International comparison, not a confirmed Russian development. Abstract-level findings do not establish human benefit; full dosing, effect sizes and bias appraisal remain needed.
- Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Reviewed 2026-10-17.
Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1.
Guan J, Gluckman P, Yang P, Krissansen G, Sun X, Zhou Y, Wen J, Phillips G, Shorten PR, McMahon CD, Wake GC, Chan WH, Thomas MF, Ren A, Moon S, Liu DX · Scientific reports (2014); PMID 24633053
The investigators reported context-dependent modulation of IGF-1 activity and modeled altered binding to IGFBP-3. Animal experiments reported improved ischemic recovery and inhibited lymphoma growth.
- Population / setting
- Cell culture, mathematical modeling, rat ischemic brain injury and mouse tumor experiments
- Source reviewed
- Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
- Multiple experimental systems do not establish a clinical mechanism or treatment benefit. The IGF-1 measurements and the Russian AMPA/TrkB experiments address different pathways.
- Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Reviewed 2026-10-17.
Transcriptomic Effects of Peptide Drug Selank during Early Experimental Cerebral Ischemia in Rats
I. B. Filippenkov, Ya. Yu. Shpetko, V. V. Stavchansky, A. E. Denisova, L. V. Gubsky, L. A. Andreeva, N. F. Myasoedov, S. A. Limborska, L. V. Dergunova · Molecular Biology. 2026;60:530–542.
At 4.5 hours after arterial occlusion, Selank was associated with 118 differentially expressed genes; 99 were downregulated. Several ischemia-associated immune-expression changes were partly reversed.
Results and tables
Reported findings and study design
Three rat groups, five per group; RNA sequencing three per group. Selank 300 micrograms/kg IP at 90 minutes and 2.5 hours after arterial occlusion; tissue at 4.5 hours.
Population or model Three groups of five rats; RNA sequencing used three animals per group
Dose, route and schedule
300 micrograms/kg intraperitoneally at 90 minutes and 2.5 hours after occlusion began. Tissue was collected at 4.5 hours. Experimental animal regimen.
Protocol source ↗ · Publisher methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Differentially expressed genes | 118 | |
| Downregulated genes | 99 | Subset of the 118 differentially expressed genes |
| Endpoint timing | 4.5 hours after occlusion | Early molecular endpoint, not a functional recovery assessment |
Uses the previously reviewed publisher methods/results; related program datasets may overlap.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Three groups of five rats; RNA sequencing used three animals per group
- Source reviewed
- Publisher full-text methods and results checked; no independent reanalysis.
Study limitations
- Early molecular endpoints do not establish functional recovery or human stroke benefit.
- Small RNA-sequencing groups; related program datasets must be checked before treating reports as independent replication.
Reviewed 2026-10-11.
[Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischemia].
Medvedeva EV, Dmitrieva VG, Povarova OV, Limborskaia SA, Skvortsova VI, Miasoedov NF, Dergunova LV · Molekuliarnaia biologiia; 2014
PGP altered expression of 29 genes at three hours and 57 at 24 hours; immune-response genes were predominantly downregulated at the later time point.
- Population / setting
- Rat cortical tissue at 3 and 24 hours after permanent focal ischemia
- Source reviewed
- Indexed primary-publication abstract checked; full methods not appraised.
Study limitations
- PGP was tested separately; results cannot be assigned wholesale to Semax or Selank.
- Gene-expression endpoints do not establish clinical stroke efficacy.
Reviewed 2026-10-11.
Cortexin modulates OPG/RANK/RANKL and TRPC1 expression in cerebral ischemia-reperfusion injury.
Guven C, Türk A, Koçak S, Zencirci B, Yalcin A, Aydın H, Doğukan M · Neurological research. 2026.
Cortexin reduced measured oxidative stress and expression of OPG, RANK, RANKL and TRPC1 in rat brain tissue after ischemia/reperfusion.
- Population / setting
- 35 male Wistar rats in five ischemia/reperfusion and comparator groups
- Source reviewed
- Indexed primary-publication abstract checked; full methods and tables not appraised.
Study limitations
- Biomarker findings in rats do not establish functional recovery or benefit in human stroke.
- The abstract does not describe blinding or group assignment.
Reviewed 2026-10-08.
[Effects of introduction of short peptides before carotid artery occlusion on behaviour and caspase-3 activity in the brain of old rats].
Mendzheritskiĭ AM, Karantysh GV, Ivonina KO · Advances in gerontology = Uspekhi gerontologii; 2011
The report describes increased behavioral sleep and reduced exploratory, motivational and motor behavior after Pinealon pretreatment. It also reports a survival signal across peptide treatment and changes in caspase-3.
- Population / setting
- Old rats given peptides before carotid-artery occlusion
- Source reviewed
- Indexed publication and abstract checked; full methods and risk of bias have not been independently assessed.
Study limitations
- Behavioral sleep in this injury model is not a measurement of human REM sleep.
- Reduced activity is not necessarily restorative sleep or improved cognition.
- Pretreatment before experimental ischemia is not evidence for treatment after a human stroke; numerical survival effects are not supplied in the abstract.
Reviewed 2026-10-06.
[The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cerebrovascular accidents].
Shchulkin AV, Chernykh IV, Abalenikhina YV, Gatsanoga MV, Kochetkova DL, Kruzhalov NA, Krestinina EV, Yakusheva EN · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2026
In a rat ischemia–reperfusion model, Cortexin did not significantly reduce lesion volume (32.75±4.91% versus 38.16±5.98%; p=0.198). Selected inflammatory/apoptosis markers changed, but BDNF did not.
Results and tables
Reported findings and study design
Reported findings
Cortexin changed selected inflammatory/apoptosis markers but did not significantly reduce lesion volume or change BDNF.
Male Wistar rats after 60-minute middle-cerebral-artery occlusion; saline, Mexidol, Cerebrolysin and Cortexin comparisons. Five rats per biochemical group; this is not a verified lesion-volume denominator.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cortexin: necrosis volume | 32.75±4.91% versus 38.16±5.98% in saline controls | Original report does not establish a reduction in brain injury · 24 hours after reperfusion · p=0.198; nonsignificant |
| Cerebrolysin: necrosis volume | 32.57±3.31% versus 38.16±5.98% in saline controls | 24 hours · p=0.176; nonsignificant |
| Mexidol: necrosis volume | 20.48±2.33% versus 38.16±5.98% in saline controls | 24 hours · p<0.001 |
| Cortexin: BDNF and cell-death markers | BDNF unchanged; TNF-α, Fas and bax reduced | Numerical marker values not provided in the abstract; Cortexin-related caspase-3 reduction not reported |
| Biochemical group sizes | Five animals per group; not assumed to be the lesion-volume analysis denominator |
Marker changes do not establish smaller infarcts, functional recovery or human benefit. The Cortexin and Cerebrolysin lesion-volume comparisons were neutral.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Male Wistar rats after cerebral ischemia–reperfusion
- Source reviewed
- Original indexed abstract and numerical lesion-volume comparisons checked through Europe PMC / PubMed; full tables not appraised.
Study limitations
- The stronger result was reported for Mexidol.
- Biochemical analyses used five animals per group; assessment was at 24 hours.
- A neutral tissue-injury result alongside biomarker changes does not establish clinical stroke benefit.
Reviewed 2026-11-06.
Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.
Filippenkov IB, Shpetko YY, Ales DA, Stavchansky VV, Denisova AE, Yuzhakov VV, Fomina NK, Gubsky LV, Andreeva LA, Myasoedov NF, Limborska SA, Dergunova LV · International journal of molecular sciences; 2025 Jun
Semax partially countered ischemia-associated gene-expression changes in the striatum. The response was smaller than previously reported in the frontal cortex.
- Population / setting
- Rat striatum, 24 hours after transient middle cerebral artery occlusion
- Source reviewed
- Indexed record and abstract checked. Full methods and risk of bias have not been independently assessed. Open full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12249733/
Study limitations
- Uses the same animals as the 2024 frontal-cortex paper; not independent replication.
- The reported worsening of 152 inflammation-associated genes concerned ACTH(6–9)PGP, not Semax.
- Transcriptomic changes do not establish human stroke recovery.
Reviewed 2026-10-06.
ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.
Filippenkov IB, Shpetko YY, Stavchansky VV, Denisova AE, Gubsky LV, Andreeva LA, Myasoedov NF, Limborska SA, Dergunova LV · Biomedicines; 2024 Dec
Semax and ACTH(6–9)PGP partly countered ischemia-associated gene-expression changes involving neurotransmission and inflammation.
- Population / setting
- Rat frontal cortex, 24 hours after transient middle cerebral artery occlusion
- Source reviewed
- Indexed record and abstract checked. Full methods and risk of bias have not been independently assessed. Open full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC11673339/
Study limitations
- The 2025 striatal analysis used these same animals.
- Different peptides and brain regions must be distinguished.
- Gene-expression endpoints do not establish patient benefit.
Reviewed 2026-10-06.
Neuroprotective effect of GK-2, a dipeptide mimetic of nerve growth factor, during experimental focal ischemia in middle cerebral artery basin
Seredenin SB, Silachev DN, Gudasheva TA, Pirogov YA, Isaev NK · Bulletin of experimental biology and medicine · PMID 22462051
GK-2 reduced infarct area and improved neurological tests.
- Population / setting
- Rats with focal cerebral ischemia after middle cerebral artery occlusion
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Animal-only finding; human stroke benefit and safety are unestablished.
Reviewed 2026-10-05.
An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2
Seredenin SB, Povarnina PY, Gudasheva TA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 30132457
GK-2 reduced infarct volume with experimental treatment starts between four and 24 hours after injury.
- Population / setting
- Rat transient middle cerebral artery occlusion; treatment-start timing experiment
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- An animal treatment window cannot be used as a human treatment window.
- No human clinical outcome was measured.
Reviewed 2026-10-05.
Design, synthesis, and neuroprotective effects of a dimeric dipeptide mimetic of the third loop of the nerve growth factor
· Primary source linked above
GTS-113 and GTS-115 were designed from NGF loop 3. GTS-115 showed cell protection and reduced infarct volume in a rat stroke model, but also induced hyperalgesia.
- Population / setting
- Cultured cells and rat ischemia/pain models
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Publisher abstract reviewed; full methods pending.
- Animal efficacy and pain responses do not establish human benefit or safety.
Reviewed 2026-10-05.
Mimetics of brain-derived neurotrophic factor loops 1 and 4 are active in a model of ischemic stroke in rats
Gudasheva TA, Povarnina P, Logvinov IO, Antipova TA, Seredenin SB · Drug design, development and therapy · PMID 27843294
GSB-106 and GSB-214 reduced infarct volume by approximately 66% and 28%, respectively, in this experiment.
- Population / setting
- Rat middle cerebral artery occlusion plus HT-22 signaling assays
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Animal results do not establish benefit or comparative potency in people.
- Effects are compound-specific and cannot be assigned to all BDNF mimetics.
Reviewed 2026-10-05.
Study of the neuroprotective effect of NT-3 dipeptide mimetics GTS-301 and GTS-302 on an experimental model of ischemic stroke
D. M. Nikiforov, P. Yu. Povarnina, T. A. Gudasheva · Pharmacokinetics and Pharmacodynamics. 2026;(1):12–19
GTS-302 reduced infarct volume by 39% and improved the day-three neurological measure; GTS-301 was inactive in this experiment.
- Population / setting
- Rats with middle cerebral artery occlusion
- Source reviewed
- Publisher-deposited abstract and metadata reviewed through Crossref; publisher website could not be retrieved.
Study limitations
- Animal experiment, not evidence of benefit in human stroke.
- Full methods, sample size and risk of bias require review.
- This is a separate stroke paper; the correction to an earlier NT-3 withdrawal study does not resolve or invalidate this paper automatically.
Reviewed 2026-10-05.
Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate Neurotoxicity.
Povarnina PY, Kolyasnikova KN, Nikolaev SV, Antipova TA, Gudasheva TA · Bulletin of experimental biology and medicine
CPG improved selected neurological and locomotor measures after incomplete global ischemia in rats and protected HT-22 cells against glutamate toxicity.
- Population / setting
- Rat ischemia model and HT-22 cells
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Brain Protein Expression Profile of Semax in a Rat Model of Cerebral Ischemia–Reperfusion
Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted · Journal publication
Olga Yu Sudarkina, Ivan B Filippenkov, Vasily V Stavchansky, Alina E Denisova, Vadim V Yuzhakov, Larisa E Sevankaeva, Liya V Valieva, Julia A Remizova, Veronika G Dmitrieva, Leonid V Gubsky, Nikolai F Myasoedov, Svetlana A Limborska, Lyudmila V Dergunova · Int J Mol Sci. 22(12):6179
At 24 hours in a rat ischemia model, Semax lowered activated JNK in two brain regions and raised activated CREB in the subcortex by more than 1.5-fold.
Results and tables
Reported findings and study design
A 90-minute middle cerebral artery occlusion followed by reperfusion. The investigators compared Semax-treated rats, saline-treated rats with ischemia, and a saline-treated sham group. Protein analysis used animals with MRI-confirmed subcortical lesions in the ischemia groups.
Population or model Male Wistar rats. Figures 2–3 report 5–7 animals per group for Western blots.
Dose, route and schedule
100 μg/kg intraperitoneal Semax per injection, first immediately after artery occlusion and again 1.5 and 5 hours after reperfusion began. Control groups received saline at the same time points.
Protocol source ↗ · Original article, methods and Figures 2–3
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Activated JNK | Over two-fold higher after ischemia than sham and more than 1.5-fold lower with Semax than with saline after ischemia | Subcortex and adjacent frontoparietal cortex · 24 hours after occlusion · p<0.05, Figure 2 |
| Activated CREB | More than 1.5-fold higher with Semax than with saline after ischemia | Subcortex. The cortical change was not statistically significant. · 24 hours after occlusion · p<0.05, Figure 2 |
| MMP-9 and c-Fos protein | Each fell by more than 1.5-fold with Semax compared with the saline ischemia group | Frontoparietal cortex. No significant treatment difference in subcortex. · 24 hours after occlusion · p<0.05, Figure 3 |
The experiment measures four selected proteins at one time point in a rat model. It provides no human treatment outcomes.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- Male Wistar rats. Figures 2–3 report 5–7 animals per group for Western blots.
- Source reviewed
- Original article, methods and Figures 2–3
Study limitations
- Animal molecular endpoints do not demonstrate clinical stroke efficacy.
- Related transcriptomic and protein studies are not automatically independent replication.
Reviewed 2026-11-16.
Insight into Glyproline Peptides' Activity through the Modulation of the Inflammatory and Neurosignaling Genetic Response Following Cerebral Ischemia-Reperfusion.
Stavchansky VV, Filippenkov IB, Remizova JA, Denisova AE, Mozgovoy IV, Gubsky LV, Myasoedov NF, Andreeva LA, Limborska SA, Dergunova LV · Genes
PGP and PGPL did not reproduce Semax’s gene-expression response after cerebral ischemia in rats. Most measured genes remained unchanged with the shorter peptides, underscoring that a shared PGP motif does not imply equivalent effects.
- Population / setting
- Rat transient middle cerebral artery occlusion; gene-expression assays
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Pharmacological treatment of memory disorders caused by hypoxia and cerebral ischemia in rats
Author transcription pending · Aviakosm Ekolog Med. 32(1):55–60
The indexed abstract identifies GVS-111 among nootropics investigated in hypoxia/ischemia-associated memory impairment.
- Population / setting
- Rat hypoxia / cerebral-ischemia memory models
- Source reviewed
- Indexed primary abstract identified; full author list and methods remain pending.
Study limitations
- Original results and compound-specific effects require full-paper extraction.
- Not a human occupational trial.
Reviewed 2026-09-29.
Histostructural changes of rat cerebral cortex during hemorrhagic stroke modeling
Savos'ko SI, Chaĭkovs'kyĭ IuB, Pogoriela NKh, Makarenko OM · Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) · PMID 23233944
Investigators reported fewer degenerating cortical neurons with the tested preparations.
Results and tables
Reported findings and study design
Rat primary/secondary hemorrhagic-stroke model comparing Cerebrolysin, Cortexin and a separately named Cerebral preparation.
Population or model Rat models of primary and secondary hemorrhagic stroke; brain histology
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Degenerative neurons after secondary stroke | 25.5 ± 0.8 cells/mm² | |
| After Cerebrolysin | 17.6 ± 1.7 cells/mm² | |
| After Cortexin | 18.0 ± 0.9 cells/mm² | |
| After Cerebral comparator | 10.7 ± 0.4 cells/mm² | |
| Healthy-control value | 1.5 ± 0.1 cells/mm²; no more than 2% degenerative neurons |
Cerebral is a separate named comparator; its larger numerical effect is not attributed to Cerebrolysin or Cortexin.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rat models of primary and secondary hemorrhagic stroke; brain histology
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Histological changes in rats do not establish human functional recovery or safety in brain hemorrhage.
- A separately named preparation, Cerebral, is not treated as interchangeable with Cortexin or Cerebrolysin.
Reviewed 2026-10-05.
Adjacent research
Mexidol in chronic cerebral ischemia: the MEMO placebo-controlled trial
A. I. Fedin, V. V. Zakharov, M. M. Tanashyan, and colleagues · Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7–16. NCT06834490.
The 318-person MEMO trial reported a 2.05-point MoCA advantage at treatment end for chronic cerebral ischemia (95% CI 1.51–2.58). Adverse events affected 15/159 with Mexidol and 21/159 with placebo.
Results and tables
Reported findings and study design
Multicenter double-blind randomized trial. The primary endpoint was change in Montreal Cognitive Assessment score from screening to the final visit.
Population or model 318 randomized, 159 per group at 15 Russian and Uzbek centers. The paper’s end-of-treatment MoCA analysis included 157 and 155.
Dose, route and schedule
500 mg Mexidol intravenously once daily for 14 days, followed by 250 mg Mexidol Forte orally three times daily for 60 days. The control group received matching placebo on the same schedule.
Protocol source ↗ · Original journal methods and Tables 3 and 9, with ClinicalTrials.gov results reviewed.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MoCA change | +4.22 vs +2.17 points | Mexidol vs placebo, 157 vs 155 in Table 3. · Between-group difference 2.05 (95% CI 1.51–2.58), p<0.000001 |
| Digit symbol substitution | +8.00 vs +5.00 points | Median change by last visit. |
| Fatigue scale (MFI-20) | −8.33 vs −4.80 points | p=0.010 |
| Participants with adverse events | 15/159 vs 21/159 | The paper reports no serious adverse events. · p=0.288 |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 318 randomized, 159 per group at 15 Russian and Uzbek centers. The paper’s end-of-treatment MoCA analysis included 157 and 155.
- Source reviewed
- Original journal methods and Tables 3 and 9, with ClinicalTrials.gov results reviewed.
Study limitations
- The 74-day trial measured cognitive scores in chronic cerebral ischemia. Effects on long-term independence and acute stroke recovery remain uncertain.
- The registry and secondary analyses report the same trial and use different denominators for some analyses.
Reviewed 2026-11-14.
Vinpotropil in chronic cerebrovascular cognitive impairment
V. V. Zakharov · Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(11 Pt 1):13–16.
The multicenter report describes improvement on repeat executive-function testing and in several self-reported symptoms after three months.
Results and tables
Reported findings and study design
Findings described in words
Multicenter before-and-after report in 349 patients given oral vinpocetine plus piracetam for three months.
Population or model 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.
Dose, route and schedule
One capsule containing 5 mg vinpocetine and 400 mg piracetam, three times daily for three months.
Protocol source ↗ · Indexed English abstract of the original Russian journal report.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Executive function and neurological symptoms | Improvement on repeat testing and symptom ratings was reported. | Three months |
The abstract does not report comparative effect sizes or adverse-event counts.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.
- Source reviewed
- Indexed English abstract of the original Russian journal report.
Study limitations
- The indexed abstract describes a treated cohort. It gives no independent comparator, effect sizes, arm counts or numerical adverse-event rates.
Reviewed 2026-11-14.
Vinpotropil in early chronic cerebral ischemia: open study
O. V. Vorob’eva, E. S. Tamarova · Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(9):39–42. Reprinted in National Journal of Neurology (2012).
Mean MMSE rose by a reported 1.9 points in the 13 patients with stage II disease. Fifteen of 20 participants rated the response good or very good. Objective neurological deficit was unchanged.
Results and tables
Reported findings and study design
Open single-cohort study, n=20. All 20 completed treatment and cognitive testing. Seven had stage I and 13 had stage II disease.
Population or model 20 patients aged 50–78. Seven with stage I and thirteen with stage II disease. Single treated cohort.
Dose, route and schedule
Two capsules orally three times daily before meals for 30 days alongside existing care. Each capsule contained 5 mg vinpocetine and 400 mg piracetam.
Protocol source ↗ · Indexed original abstract and the credited 2012 journal republication.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mean MMSE change in stage II subgroup | +1.9 points (n=13) | Baseline 26.2 ± 2.4, day 30 28.2 ± 2.4. The published change is 1.9 points. · Day 30 |
| Patients rating response good or very good | 15/20 (75%) | Day 30 |
| Objective neurological deficit | Unchanged. | |
| Reported adverse effects | None in the 20 patients during 30 days. |
The 2012 republication credits the 2010 original (DOI 10.61788/njn.v1i12.14). A comparator is needed to estimate a treatment effect.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 20 patients aged 50–78. Seven with stage I and thirteen with stage II disease. Single treated cohort.
- Source reviewed
- Indexed original abstract and the credited 2012 journal republication.
Study limitations
- Repeated cognitive testing and background care may influence the change. The two publication versions describe the same patients. The study addressed chronic cerebral ischemia.
Reviewed 2026-11-14.
Picamilon in stage I and II chronic cerebral ischemia: open comparative study
Format: Publisher HTML article · Reviewed: Methods and results
A. B. Danilov, N. N. Shindryaeva, I. V. Borodulina, T. D. Lunev · Consilium Medicum. 2025;27(2)
In the 2025 open Picamilon comparison, MoCA increased from 24.9 to 28.3 in stage I disease and from 20.9 to 25.9 in stage II disease. Sleep and symptom scores also improved; there was no placebo or untreated group.
Results and tables
Reported findings and study design
In the 2025 open Picamilon comparison, MoCA increased from 24.9 to 28.3 in stage I disease and from 20.9 to 25.9 in stage II disease. Sleep and symptom scores also improved; there was no placebo or untreated group.
100 enrolled: stage I 50 (oral 25; sequential injection/oral 25), stage II 50. Efficacy analyzed in 94 completers; all 100 in safety. Treatment 60 days (I) or 70 days (II); follow-up 45 days later.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MoCA score, mean ± SD | Stage I: 24.9 ± 3.78 → 26.5 ± 2.77 → 28.3 ± 2.18; stage II: 20.9 ± 4.79 → 24.6 ± 3.64 → 25.9 ± 3.88 | Within-stage values; not randomized disease-stage comparison · Baseline → end of treatment → 45-day follow-up |
| Sleep score, mean ± SD | Stage I: 19.7 ± 3.77 → 22.7 ± 3.46 → 24.3 ± 3.06; stage II: 18.5 ± 4.01 → 21.8 ± 3.61 → 22.8 ± 3.01 | Levin subjective questionnaire; higher is better · Same visits |
| Adverse events | 4/50 stage I; 4/50 stage II; none serious or causing discontinuation | All 100 enrolled patients in safety analysis · Treatment period |
| Attrition | 6/100 did not complete; efficacy used 94 completers | Withdrawals reported unrelated to adverse reactions |
Cognition, autonomic symptoms, neurological symptoms and sleep — Tables 3–6
| Measure / group | Baseline mean (SD) | End-treatment mean (SD) | Follow-up mean (SD) | Within-group tests |
|---|---|---|---|---|
| MoCA · stage I | 24.9 (3.78) | 26.5 (2.77) | 28.3 (2.18) | baseline→end p=0.022; end→follow-up p<0.0001 |
| MoCA · stage I oral | 23.8 (4.44) | 25.8 (3.37) | Not separately listed | p=0.065 |
| MoCA · stage I sequential | 26.1 (2.9) | 27.2 (1.73) | Not separately listed | p=0.161 |
| MoCA · stage II | 20.9 (4.79) | 24.6 (3.64) | 25.9 (3.88) | p<0.0001; p=0.0006 |
| Vein autonomic scale · I | 26.7 (14.0) | 17.3 (12.2) | Not measured | p<0.0001 |
| Vein scale · I oral | 29 (14.9) | 19.2 (12.3) | Not measured | p=0.0004 |
| Vein scale · I sequential | 24.1 (12.9) | 15.2 (12) | Not measured | p=0.007 |
| Vein scale · II | 25.3 (13.1) | 18.3 (15.2) | Not measured | p=0.0014 |
| Fedin neurological scale · I | 11.9 (8.3) | 6 (6.1) | 2.77 (4.43) | p<0.0001; p<0.0001 |
| Fedin · I oral | 12.4 (8.12) | 5.61 (5.12) | Not separately listed | p=0.0006 |
| Fedin · I sequential | 11.3 (8.65) | 6.43 (7.12) | Not separately listed | p=0.004 |
| Fedin · II | 17.4 (9.34) | 8.06 (6.84) | 5.31 (5.71) | p<0.0001; p=0.0002 |
| Levin sleep · I | 19.7 (3.77) | 22.7 (3.46) | 24.3 (3.06) | p<0.0001; p=0.0002 |
| Levin sleep · I oral | 20.0 (4.37) | 23.7 (3.72) | Not separately listed | baseline→end p=0.0026 |
| Levin sleep · I sequential | 19.3 (3.04) | 21.5 (2.80) | Not separately listed | p=0.0051 |
| Levin sleep · II | 18.5 (4.01) | 21.8 (3.61) | 22.8 (3.01) | p<0.0001; p=0.009 |
Tables transcribed from the publisher PDF text, printed pp.103–105; visual page inspection unavailable. Stage I visit 2 sleep: 20.7 (3.19), oral 20.9 (3.63), sequential 20.4 (2.69); stage II 19.3 (4.05). MoCA/Levin higher is better; Vein/Fedin lower is better. Subgroup MoCA changes were not significant.
Arginine biomarkers — original Table 10
| Measure / stage | Baseline median (Q1; Q3) | End-treatment median (Q1; Q3) | Paired p |
|---|---|---|---|
| ADMA · I (n=37) | 159 (146; 167) | 135 (108; 157) | 0.001 |
| SDMA · I | 179 (163; 212) | 179 (129; 199) | 0.104 |
| ADMA/MMA · I | 14.5 (13.4; 15.3) | 12 (11.1; 12.4) | <0.001 |
| (ADMA+SDMA)/MMA · I | 31.4 (28.3; 32.8) | 26.3 (23.4; 29.6) | <0.001 |
| SDMA/MMA · I | 17.3 (13.9; 18) | 14.2 (12.2; 17.4) | 0.002 |
| ADMA · II (n=42) | 167 (148.5; 177) | 138 (115.5; 152) | <0.001 |
| SDMA · II | 195 (173; 234) | 186 (148.5; 233) | 0.037 |
| ADMA/MMA · II | 14.3 (13.15; 15.3) | 11.2 (10.85; 12) | <0.001 |
| (ADMA+SDMA)/MMA · II | 33.3 (28.65; 35.8) | 26.4 (23.2; 31.5) | <0.001 |
| SDMA/MMA · II | 18.1 (14.9; 20.25) | 15.7 (12.15; 19.25) | 0.002 |
Publisher PDF text, printed p.106. ADMA/SDMA concentrations in ng/mL; ratios unitless. Biomarker subset 79, not the full 100. Stage I SDMA did not significantly change. Other vascular tables remain to be visually checked before full transcription.
This paper may overlap with the 2024 Picamilon reports; their participants must not be added as independent cohorts. Active-treatment improvements and blood markers do not establish prevention of stroke or cardiovascular events.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 100 enrolled; 94 in per-protocol efficacy analysis; stage I and II groups initially 50 each
- Source reviewed
- Original publisher PDF methods and Tables 3–7, 10 text reviewed; visual table verification and complete Doppler-table transcription remain open
Study limitations
- No untreated or placebo group.
- Shared investigators, protocols and cohort characteristics suggest possible overlap with the 2024 reports; this is an inference, not confirmed participant identity.
- The three reports list 44, 50 and 100 participants. The extent of overlap is unknown.
Reviewed 2026-11-01.
Clinical efficacy and safety of Picamilon in patients with progressive chronic cerebral ischemia
Format: Publisher HTML article · Reviewed: Original publisher abstract and selected HTML results checked; patient-series overlap remains unresolved
Danilov AB, Shindryaeva NN, Borodulina IV, Lunegov TD, Kristeleva DA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 124(8). PMID 39269299
In an uncontrolled 50-person stage II cohort, cognition and sleep questionnaire scores improved during treatment and follow-up.
Results and tables
Reported findings and study design
In an uncontrolled 50-person stage II cohort, cognition and sleep questionnaire scores improved during treatment and follow-up.
50 patients; 10 days intravenous treatment followed by 60 days oral treatment; final follow-up 1.5 months later.
Population or model 50 stage II patients (5 men, 45 women); 70-day active treatment and 45-day follow-up
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MoCA cognitive score | 20.9 → 24.6 → 25.9 points | Baseline → end of treatment → delayed follow-up · p<0.0001 and p=0.0006 as reported |
| Sleep normalization | 55% → 81% | End of treatment → delayed follow-up; questionnaire-defined · p<0.0001 and p=0.0025 |
| Fedin neurological score | 17.4 ± 9.34 → 8.06 ± 6.84 → 5.31 ± 5.71 points | Baseline → visit 2 → visit 3 · p<0.0001 and p=0.0002 |
| Neurological improvement | 84% | Within treated cohort |
| Autonomic findings | 38% normalized; 60% had reduced symptom severity | Separate response categories · p=0.0001 as reported |
| Reported tolerability | 98% | Uncontrolled cohort; not a placebo safety comparison |
No untreated comparator was included. Questionnaire sleep changes do not describe deep or REM sleep. Clinical-event prevention is not established by these scale and vascular-marker changes.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 50 stage II patients (5 men, 45 women); 70-day active treatment and 45-day follow-up
- Source reviewed
- Original publisher abstract and selected HTML results checked; patient-series overlap remains unresolved
Study limitations
- Uncontrolled treatment cohort; expectation, repeated testing and concomitant care can affect outcomes.
- Questionnaire improvement is not evidence about wearable sleep stages.
- Strong similarities to the 2025 stage II group warrant overlap checks before any pooling.
Reviewed 2026-11-01.
Cerluten: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes attention-test and selected EEG improvements during 10–20 days of adjunctive treatment.
- Population / setting
- 85 patients: 48 adjunctive Cerluten; 37 conventional-care controls. Mixed neurological diagnoses.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- Random allocation and blinding are not documented. EEG assessment selected more severely affected patients; the findings cannot establish stroke recovery or benefit in healthy people.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-10-02.
Results of a multicenter observational program to evaluate the effectiveness of complex therapy of patients with chronic cerebrovascular pathology with cognitive impairment with Cortexin and Neuromexol (CORNELia study)
Mashin VV, Belova LA, Kotova EY, Dolgova DR, Statenina AP, Belyaeva YK, Dergacheva AS, Israfilova RR · Zh Nevrol Psikhiatr Im S S Korsakova 123(12):34-41. PMID 38147380
Reports clinical changes with Cortexin plus Neuromexol; biomarkers were assessed in smaller comparison subgroups.
Results and tables
Reported findings and study design
801 chronic-ischemia patients, ages 30–80: 329 men and 472 women. Biomarker subset 30 combination-treated versus 30 comparison patients. Cortexin 10 mg/day for ten days plus Neuromexol 375–750 mg/day for 30 days.
Population or model CORNELia; 801 patients with chronic cerebral ischemia and cognitive impairment
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| NSE biomarker change | Twofold decrease in combination-treated subset | p<0.05 |
| MMSE and drawing-test correlation | r=0.5 before and r=0.6 after treatment | p<0.05 |
| Anti-NR2 antibodies | Decreased in both groups | p<0.05 |
| VEGFA | Decreased only in combination-treated subset | p<0.05 |
Biomarker comparisons use the 30/30 subset, not all 801 patients; treatment combines two drugs.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- CORNELia; 801 patients with chronic cerebral ischemia and cognitive impairment
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- Combination treatment does not isolate Cortexin’s contribution.
- The biomarker subset is not the full cohort; observational findings do not establish causality.
Reviewed 2026-09-29.
Treatment of asthenic syndrome in chronic brain ischemia: TRIUMPH observational program
Format: Publisher HTML article · Reviewed: Publisher full-text results narrative and available tables checked on 1 November 2026
A. I. Fedin, E. Yu. Solovyeva, O. P. Mironova, A. V. Fedotova · Zh Nevrol Psikhiatr Im S S Korsakova. 114(12):104–111
Fatigue scores declined in an observational program, with large exclusions from analysis and no untreated group.
Results and tables
Reported findings and study design
Fatigue scores declined in an observational program, with large exclusions from analysis and no untreated group.
2,029 enrolled; 1,170 analyzed; 859 excluded for protocol/documentation problems. Physicians chose two or three months of 100 mg/day treatment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| General-fatigue reduction at three months | 59.1%, 55.9%, 60.5% and 55.7% | Four age-by-duration subgroups; within-person reductions, not a placebo-adjusted effect · Three months after treatment started |
| Post-treatment MFI-20 score | 33.3 points in younger patients; 37.0 in older patients | Ages 45–54 and 55–65; reported overall baseline score 77 · Final follow-up |
| Baseline severity versus subsequent reduction | r=0.789 | Correlational association · p=0.001 |
| Analysis population | 1,170 of 2,029 participants | 859 records excluded; not all enrollment contributed to results |
Reported fatigue reductions by age and treatment duration
| Age / course | General fatigue | Physical fatigue | Reduced activity | Reduced motivation | Mental fatigue |
|---|---|---|---|---|---|
| 45–54 / 2 months | 59.1% | 53.9% | 57.0% | 49.8% | 58.6% |
| 55–65 / 2 months | 55.9% | 48.6% | 53.4% | 47.6% | 55.6% |
| 45–54 / 3 months | 60.5% | 50.7% | 58.9% | 52.2% | 58.6% |
| 55–65 / 3 months | 55.7% | 46.9% | 54.0% | 50.0% | 55.4% |
Reductions from each subgroup baseline at three months after initiation; the two-month groups were assessed one month after stopping. The narrative does not provide subgroup denominators here.
Treatment duration was not randomized and there was no placebo or untreated comparator. The table preserves each subgroup rather than assigning the largest percentage to the whole cohort.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 2,029 participants; 1,170 analyzed; 859 excluded for protocol completion/documentation problems
- Source reviewed
- Publisher full-text results narrative and available tables checked on 1 November 2026
Study limitations
- Large exclusion from analysis creates potential selection bias.
- No untreated control; within-person improvement cannot establish causation.
- This program is not a randomized trial and cannot establish long-term safety.
Reviewed 2026-11-01.
CHRONAS: pilot study of chronic sleep disorders in patients with chronic cerebral ischemia
M. V. Putilina, N. I. Shabalina · Zh Nevrol Psikhiatr Im S S Korsakova 124(4):118–126
Prospective pilot report using sleep, sleepiness and other clinical questionnaires. The abstract describes changes after treatment, but does not describe a randomized untreated control.
Results and tables
Reported findings and study design
CHRONAS: 50 patients, age 50.4 ± 2.26, with chronic cerebral ischemia and comorbid sleep problems. Cortexin 10 mg IM for ten days; assessments around days 11–15 and 30–31.
Population or model 50 patients with chronic cerebral ischemia and comorbidities
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Timing of reported symptom changes | By days 11–15; maintained about one month | |
| Sleep and cognition scores | Improvement described | No numerical PSQI/MMSE change or untreated comparison in abstract |
| Observed adverse drug interactions | None reported | With antihypertensives, antiplatelets and statins in this cohort |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 50 patients with chronic cerebral ischemia and comorbidities
- Source reviewed
- English/Russian abstract checked. No wearable sleep-stage results are inferred.
Study limitations
- Clinical population differs from healthy maritime shift workers.
- Before/after change does not isolate a treatment effect.
- Questionnaires cannot validate the personal WHOOP REM/SWS observations.
Reviewed 2026-09-27.
An open clinical trial of cortexin in treatment of brain ischemia
V. V. Mashin, L. A. Belova, O. I. Chaplanova, A. F. Khusnullina, A. M. Manasian · Zh Nevrol Psikhiatr Im S S Korsakova. 114(9):49–52
The authors describe before/after cognitive, affective, and neurological changes in an open treatment analysis.
Results and tables
Reported findings and study design
Open screening program: 50,000 patients in 70 cities; analyzed subgroup 500 with stage-II brain ischemia, mean age 63.7 ± 10.23. Cortexin 10 mg/day for ten days; assessments before treatment and days 11 and 30.
Population or model Analysis of 500 patients with stage II brain ischemia
Dose, route and schedule
Cortexin: 10 mg/day for ten days. The route is not specified in the indexed abstract.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Analyzed treatment sample | 500 | The 50,000-person screening program is not the analyzed trial sample |
| Cognitive/affective and focal symptoms | Improvement reported | No numerical score changes supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Analysis of 500 patients with stage II brain ischemia
- Source reviewed
- PubMed record and English abstract checked. Open interventional report; grouped here with uncontrolled observational evidence.
Study limitations
- No untreated comparison is described in the abstract.
- The analysis sample is 500; the larger screening population is not the analyzed sample.
- This paper did not measure wearable sleep stages and cannot validate the n=1 diary.
Reviewed 2026-09-27.
Needs reconciliation
Safety and feasibility of cerebrolysin in treatment of primary intracerebral hemorrhage (CLINCH)-a prospective, randomized, open-label, blinded endpoint pilot trial.
Kobayashi A, Rutkowska K, Gocyla-Dudar K, Chelstowska B, Pozarowszczyk N, Karlinski M · Frontiers in neurology; 2025
The paper describes a planned randomized, open-label, blinded-endpoint pilot comparing Cerebrolysin plus standard care with standard care alone. It does not report completed trial outcomes.
Results and tables
Reported findings and study design
CLINCH trial protocol, not results: planned 88 lobar-hemorrhage patients, 1:1 allocation within six hours. IV Cerebrolysin 50 mL/day for 14 days plus standard care versus standard care.
Population or model CLINCH protocol: planned enrollment of 88 patients with lobar intracerebral hemorrhage
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Planned enrollment | 88; no enrolled/result count reported | |
| Eligibility | Hemorrhage volume 30–80 mL; GCS 8–15; NIHSS≥8 | |
| Stratification | Volume 30–50 versus 51–80 mL; GCS 8–12 versus 13–15 | |
| Planned primary outcomes | 90-day mortality and mRS 0–2 at day 90 |
All values are planned protocol parameters. None is an observed efficacy or safety result.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- CLINCH protocol: planned enrollment of 88 patients with lobar intracerebral hemorrhage
- Source reviewed
- Indexed record and available abstract checked; full text not reviewed. Study type is based on the database record and abstract, where available.
Study limitations
- Planned enrollment is not an observed patient count.
- No efficacy or safety conclusion can be drawn from this protocol.
- Full methods and risk of bias have not been independently assessed.
Reviewed 2026-10-07.
Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials
Patel PN, Mangal D, Patel K · Cureus · PMID 41018475
The review reports a neurological-scale benefit, but functional independence and mortality were not significantly improved.
- Population / setting
- 2025 meta-analysis reporting 14 randomized trials
- Source reviewed
- Full PMC article: study-characteristic and outcome tables 1–8 checked. Primary trial datasets and forest-plot inputs have not been independently reconstructed.
Study limitations
- Table 8 calls hemorrhagic transformation statistically significant, contrary to the abstract’s wording; the discrepancy remains in the publication.
- Tables 2, 5 and 6 list both CARS-1 and the pooled CARS report. CARS denominators also differ between tables (448 versus 240). Cohort independence and extraction need reconciliation.
- Safety totals differ between the headline sample and Table 8. Numerical pooled effects are withheld rather than treated as verified estimates.
Reviewed 2026-10-05.
Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies
Afridi A, Sajjad F, Arshad A, Shahid I, Fatima NE, Alam U, Hoti RK, Abdullah M, Khan S, GhanimAl-Badri S, Khan S, Bakkar MA, Saeed A, Ali A, Khan LA, Kamil KA · Brain and behavior · PMID 41880098
Authors report favorable recovery and safety associations, but inconsistent denominators prevent reliable interpretation of the quoted estimates.
- Population / setting
- 2026 review of three observational thrombectomy-adjunct studies
- Source reviewed
- Full PMC article: study-characteristic tables and results narrative checked. Original cohort records and repeated follow-up observations still require reconstruction.
Study limitations
- Table 1 totals 148 treated and 146 controls, while the abstract gives incompatible functional-outcome and mortality denominators.
- Mortality is pooled across several follow-up times; independence of repeated observations needs verification. Staszewski is dated 2025 in Table 1 but 2022 in the results.
- Three observational cohorts cannot establish a randomized adjunct effect. The original datasets are needed before relying on the pooled numbers.
Reviewed 2026-10-05.
Cortexin and combination of nitrite with cortexin decrease swelling and destruction of cerebellar neurons in hemorrhagic stroke
Reutov VP, Samosudova NV, Filippova NA, Krushinskii AL, Kuzenkov VS, Sorokina EG, Pinelis VG, Granstrem OK, Larionova NP, Chailakhyan LM · Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · PMID 19650315
The title describes cerebellar injury and Cortexin with or without nitrite; no outcome is extracted from the title.
- Population / setting
- Hemorrhagic-stroke paper; indexed citation without abstract
- Source reviewed
- Indexed citation reviewed via Europe PMC / PubMed; no abstract or full text reviewed. Study type is based on the database record and abstract, where available.
Study limitations
- Original methods and results were not recovered.
- No clinical efficacy or combination-safety claim can be made from this citation.
Reviewed 2026-10-05.
Original publications and open questions
This collection focuses on stroke and impaired blood flow to the brain. Related studies on altitude, heart or intestinal ischemia provide background on how the compounds were studied.
Picamilon, Cortexin in chronic cerebral ischemia, Cerluten and Phenotropil in fatigue-related disorders appear under related research. Direct evidence on human stroke outcomes remains unclear for Bemitil, Bromantane, Selank, DSIP and Hypoxen.
- The 1997 Semax full text supplies neurological scores by arm. Allocation, masking, the conflicting severe-control count, and systematic harms remain unresolved.
- Participant overlap, allocation methods and comparability with current standard care remain unclear in the Cortexin reports.
- The 2025 and 2026 Cerebrolysin review tables give counts that need confirmation from the original trials.
- The original GZK-111 focal-stroke reports would clarify its effects in that model.
- The available citations leave Picamilon and Bemitil outcomes in cerebral injury unclear.
- Long-term disability, quality of life, stroke recurrence and survival remain important clinical outcomes.
Cerebrovascular activity in the post-ischemic period
Rozhnova; Gaevy; Kovalev · 1989 · Reported Ufa proceedings citation, pp. 43–50
Exact title, pagination, participants, methods and results require original-source verification. No outcome is assigned.
Bibliography record ↗Picamilon versus piracetam in experimental ischemic and hemorrhagic brain injury
Dunaev; Bashkin; Tishkin et al. · 1989 · Reported Ufa proceedings citation, pp. 51–59
Exact title, pagination, participants, methods and results require original-source verification. No outcome is assigned.
Bibliography record ↗Bemitil preclinical archive: ischemia, poisoning, repair and reproductive effects
Individual authors and original reports pending · Date unresolved · Archival research citation lead; bibliographic details need confirmation
Targets include cerebral and myocardial injury, intestinal ischemia, peritonitis, hepatectomy, convulsions, chemical exposures and developmental toxicology. Models and formulations must be checked separately; class-level findings cannot be assigned to Bemitil automatically.
Bibliography record ↗Original publications and PDFs
Aleksandrova’s original Cortexin dissertation abstract ↗ · Mexidol MEMO registry results ↗
Every matrix row links to its source record and external publication. The Phenotropil recovery report links to a Russian PDF reprint. The 2026 NT-3 paper’s publisher PDF is a deposited link; its full text has not yet been appraised. Source availability can change.
For current acute-stroke care, see the 2026 AHA/ASA guideline. This research map does not replace specialist assessment, reperfusion decisions, prevention or rehabilitation.
Complete bibliography ↗ · Multiple sclerosis research ↗ · Research map ↗
Study findings by subject
1 source records
2026 · Comparison in people
Mexidol and cognitive testing in 90 older adults with chronic cerebral ischemia
At three months, median MMSE was 27 vs 26 points. Schulte test time fell by 8 vs 2 seconds with add-on Mexidol and standard care alone, respectively.